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T
wenty-five years into the global hiv/aids 
epidemic, hiv infection rates are alarmingly 
high, and more than 4 million people become 
infected every year.1 Despite the proven 
effectiveness of existing prevention approaches, fewer 
than one in five people at high risk for hiv have access, 
and current prevention approaches are not practical for 
everyone, especially women. New approaches to hiv 
prevention are urgently needed.
This Global hiv Prevention Working Group report 
addresses three critical areas:
1. hiv Prevention Research: State of the Science
A wide range of promising new hiv prevention 
approaches are being tested in clinical trials, including 
male circumcision, cervical barriers, pre-exposure 
prophylaxis with antiretroviral drugs, herpes suppression, 
microbicides, and hiv vaccines. The results of some of 
these studies could be available within the next two years.
2. Accelerating hiv Prevention Research
Prevention research faces serious challenges that 
could delay the completion of critical trials, or prevent 
planned trials from moving forward — including a lack of 
adequate research infrastructure in developing countries, 
limited resources, emerging ethical concerns, and 
inadequate community engagement.
3. Preparing for Access
Despite the fact that some new hiv prevention methods 
could be shown to be effective in the near future, 
virtually no planning or resources have been dedicated 
to ensuring future access to new prevention approaches. 
Key implementation issues that must be addressed 
immediately include ensuring adequate resources, 
developing public health guidelines, providing health  
care worker training, and ensuring that risk behavior 
does not inadvertently increase with the introduction of 
new prevention methods.
Unless the world acts now to accelerate hiv 
prevention research and prepare for implementation of 
effective new approaches, we risk letting new prevention 
methods sit idle while 4 million people become infected 
every year. Averting that fate is the goal of this report, and 
should be a top priority in the fight against hiv/aids.
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executive summary
about this report
A growing number of promising new hiv prevention approaches are in the late stages of clinical research, and have the 
potential to dramatically reduce the burden of hiv/aids around the world. Research on some of these approaches, such 
as male circumcision and diaphragms, could show results within the next two years.
But there are serious obstacles that could significantly delay, or even derail, critical prevention trials — including 
inadequate resources and capacity to launch and complete trials, and emerging ethical concerns. Moreover, the world is 
unprepared to capitalize on the potential success of prevention research currently underway. Very little has been done 
to mobilize resources and develop the public health guidance, provider training, and public education needed to ensure 
rapid implementation of new prevention methods.
This new report by the Global hiv Prevention Working Group, New Approaches to hiv Prevention: Accelerating 
Research and Ensuring Future Access, summarizes the state of hiv prevention research, and makes recommendations to 
speed research on promising new hiv prevention methods, and ensure rapid access to new tools and strategies as soon 
as they are proven effective.
No “Magic Bullet” for hiv
It is critical to note that there is no “magic bullet” for 
hiv prevention. None of the new prevention methods 
currently being tested is likely to be 100 percent 
effective, and all will need to be used in combination 
with existing prevention approaches if they are to 
reduce the global burden of hiv/aids.
i. hiv prevention research:  
state of the science
A wide range of promising hiv prevention approaches are 
in late-stage clinical trials:
t  Male circumcision: Researchers have long observed that 
countries with higher rates of male circumcision have 
lower rates of hiv infection. In 2005, the first randomized 
efficacy trial of male circumcision for hiv prevention, 
conducted in South Africa, showed that circumcised men 
were 60 percent less likely than uncircumcised men to 
become infected with hiv from female partners.
Three additional efficacy trials of male circumcision 
are underway in Kenya and Uganda to assess the 
applicability of the South African findings in other 
settings and populations, and to determine if male 
circumcision also reduces the risk of hiv transmission 
from men to their female partners. Results are expected 
in 2007.
t  Cervical barriers: Researchers hypothesize that cervical 
barriers such as diaphragms, which are currently used 
for contraception, may help protect women from hiv 
and other sexually transmitted diseases. An efficacy 
trial of the diaphragm for hiv prevention is nearing 
completion in South Africa and Zimbabwe, and results 
are expected in 2007.
t  Pre-exposure prophylaxis with antiretrovirals: Research 
in animals suggests that antiretroviral drugs used for hiv 
treatment may also be effective at preventing infection in 
hiv-uninfected adults, an approach called pre-exposure 
prophylaxis, or prep. Efficacy trials of this approach are 
underway in Botswana, Peru, and Thailand. Results 
could be available as early as 2007 or 2008.
t  Herpes suppression: Herpes, which infects up to  
70 percent of people in some parts of sub-Saharan Africa, 
can triple the risk of hiv acquisition, as well as increase the 
risk of transmission to others. The inexpensive, off-patent 
drug acyclovir is approved for herpes suppression, and two 
trials are being conducted in Africa, Latin America, and 
the U.S. to test the efficacy of suppressing herpes to lower 
hiv risk. Results are expected in 2007 and 2008.
t  Microbicides: Microbicides are topical substances, 
such as gels or creams, that could be applied to the 
vagina or rectum to reduce hiv transmission. Five first-
generation vaginal microbicide candidates are currently 
in late-stage clinical trials; results from some of these 
trials could be available by 2008. In addition, a number 
of second-generation microbicide candidates — which 
specifically target hiv or molecules of the cells it 
infects — are in earlier stages of research, and could 
complete clinical trials within 10 years.
t  hiv vaccines: The best long-term hope for hiv prevention 
is a vaccine, although developing an effective vaccine 
has proven to be a highly complex scientific challenge. 
Most experts predict that it could be 10 years or more 
before an hiv vaccine candidate is shown to be effective. 
An effective vaccine will likely need to stimulate two 
types of immune response, although most of the vaccine 
candidates developed to date are designed to target 
only one arm of the immune system. Currently, 30 hiv 
vaccine candidates are in clinical trials, including two in 
advanced efficacy or proof-of-concept trials.
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summary of findings and recommendations
women, hiv, and new 
prevention methods
Many of the new hiv prevention methods in 
development could be particularly beneficial for 
women, who account for roughly one-half of people 
living with hiv globally.2 For many women, current 
prevention methods are inadequate — women often  
do not have the social or economic power to refuse  
sex or negotiate condom use. 3
New tools such as cervical barriers, pre-exposure 
prophylaxis, and microbicides may provide women 
with hiv prevention methods that they could 
initiate — potentially without the knowledge or  
consent of their partners. 
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Sub-Saharan
Africa
46% 54%
57% 43%
Women Men
FIGURE 1. People Living with hiv/aids, by Gender, 2005
Source: unaids, 2005
2.  accelerating hiv 
prevention research
As new hiv prevention approaches move forward into 
advanced stages of development, the world faces serious 
financial, logistical, and ethical challenges in completing 
ongoing prevention trials, and in mounting the additional 
large-scale trials that will be needed to fully test new 
prevention tools and strategies. Key challenges — and 
recommendations from the Global hiv Prevention 
Working Group — include:
t  Clinical trials capacity: Current efficacy trials of new 
hiv prevention approaches will require a total of 
approximately 80,000 study participants. Even more 
participants will be needed to mount additional efficacy 
studies and to conduct confirmatory trials. Yet current 
global clinical trials capacity — including an adequate 
number of participants, properly equipped study sites, 
and trained research staff — falls far short of the need.
Recommendations: Trial sponsors, national governments, 
and international donors should make significant new 
investments in global capacity for hiv prevention trials. 
Agencies should work together to inventory existing 
capacity, determine specific needs in key regions, and 
identify sites for scaling up capacity. Given limited 
capacity, trial sponsors should better coordinate decision-
making about which prevention interventions to prioritize 
for large-scale trials, and share trial sites as necessary.
t  Ethical issues: While current hiv prevention trials 
are being conducted according to internationally and 
locally accepted ethical standards, existing guidelines 
do not sufficiently address some key issues that have 
emerged in recent years. These include defining the 
standard set of existing prevention methods that 
should be provided to all trial participants; defining 
and ensuring fully informed consent; and determining 
how to facilitate hiv treatment access for participants 
who become hiv-infected during the course of a trial, 
or who are found to be hiv-infected at the initial 
screening for a trial.
Recommendations: Key stakeholders in hiv prevention 
research — including trial sponsors, affected communities, 
and developing country governments — should work with 
unaids and the World Health Organization (who) to 
convene a broadly inclusive panel of experts to develop 
updated ethical guidelines for conducting hiv prevention 
research. This guidance should be continually revised as 
hiv prevention research evolves.
t  Community engagement: Community involvement and 
support are vital to successful clinical research. Yet 
some hiv prevention trials have been criticized for not 
properly reaching out to communities. In some cases, 
misinformation and lack of communication between 
researchers and communities have been factors in the 
cancellation of hiv prevention trials.
Recommendations: Investigators and sponsors of hiv 
prevention trials should foster strong partnerships with 
the communities where trials are conducted — through 
Community Advisory Boards, regular communications 
to the broader community, and involvement of key local 
and national officials. Community input should inform 
key aspects of the clinical research process, including 
development of trial protocols, recruitment of participants, 
and ongoing trial oversight. International agencies such 
as unaids and who should compile and publish best 
practices in community engagement.
FIGURE 2. Global hiv/aids Epidemic, 1990 – 2005
Source: unaids, 006
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3.  preparing for access
As soon as they are shown to be effective, new hiv 
prevention methods should be made accessible and 
affordable for people at risk. But the world is virtually 
unprepared to ensure rapid access. Key challenges and 
recommendations include:
t  Resources: While there have been significant increases 
in global spending to fight the hiv/aids epidemic 
in recent years, there are still severe resource gaps. 
unaids estimates that $11.4 billion will be needed 
annually for hiv prevention by 2008 — two-and-a-half 
times current spending.4 Ensuring timely, widespread 
access to new prevention methods will require 
significant additional resources. Many countries will 
need donor assistance to purchase new prevention 
tools such as pre-exposure prophylaxis, microbicides, 
and vaccines. New resources will also be needed to 
support provider training and community education 
programs, to ensure that new prevention methods are 
safely and properly implemented.
Recommendations: The international community —  
including major donors such as the Global Fund to Fight 
aids, Tuberculosis, and Malaria, and the U.S. government’s 
President’s Emergency Plan for aids Relief — should commit 
to providing the resources necessary to ensure the roll-out of 
new hiv prevention tools as soon as they are shown to be 
effective. It is critical to begin estimating now the resources 
that will be needed to implement new prevention methods. It 
is also vital that these resources do not take funding away from 
current hiv prevention, treatment, and care programs.
t  Public health guidance: As results become available 
from clinical trials, national and global decision-makers 
will need to carefully determine how to integrate new 
hiv prevention methods into health programs. In the 
case of new technologies such as microbicides and 
hiv vaccines, regulatory review and licensure will be 
required as well. Yet there are significant gaps in global 
capacity to provide timely public health guidance and 
regulatory review for new hiv prevention interventions.
Recommendations: Key stakeholders in hiv prevention —
including national governments, donors, and international 
agencies such as unaids and who — should establish 
systems to anticipate and provide needed guidance on the 
introduction of new prevention methods. Key issues include 
developing formal public health guidance on the proper use 
of new prevention approaches, and developing tools to help 
decision-makers in developing countries assess the relative 
cost and benefit of new prevention interventions. In addition, 
regulatory agencies in the U.S. and Europe should provide 
assistance to their counterparts in developing countries on 
evaluating new prevention methods.
t  Provider training: Health care professionals and 
community health providers will require training in the 
safe and proper use of new hiv prevention methods. 
For example, in many developing countries, few health 
care providers have experience in circumcising adult 
males, and if the procedure is improperly performed 
it can result in serious injury or death. The problem of 
health worker training is compounded by the fact that 
many developing countries suffer acute shortages of 
qualified health care personnel in general.
Recommendations: International agencies such as 
unaids and who should develop regional and country-
level provider training programs to help promote the safe 
and proper use of new hiv prevention methods. Where 
possible, training in providing new hiv prevention methods 
should be integrated into ongoing health provider training 
programs, and traditional healers should be included in 
these programs.
t  Preventing “disinhibition”: It is essential that the 
introduction of new prevention methods does not lead 
people to become complacent about hiv risk behavior. 
Such behavioral disinhibition could cancel out the 
benefits of new hiv prevention methods, and lead to 
an inadvertent increase in hiv infections
Recommendations: Strong communications and public 
education campaigns, grounded in scientific evidence 
of effectiveness, should accompany the introduction of 
new prevention methods, to reinforce the importance 
of minimizing risk behavior and using new prevention 
methods in combination with existing tools and strategies. 
It is also critical to monitor and evaluate efforts to counter 
potential disinhibition on an ongoing basis to ensure they 
are effective. 
As research moves forward on new hiv prevention 
methods, it is also critical to expand access to existing 
prevention methods.
Fewer than one in five people at high risk for hiv 
currently have access to effective prevention (see figure ).5 
According to an analysis by unaids and the World Health 
Organization, expanded access to proven prevention 
strategies could avert half of the 6 million new hiv 
infections projected to occur between 005 and 05.6
The following tools and strategies are proven to 
reduce the risk of hiv transmission:7
Preventing Sexual Transmission
t  Behavior change, including abstinence and condom 
use: A number of scientific studies have documented 
the effectiveness of behavior change programs that 
encourage people to adopt safer sexual behaviors. 
These include remaining sexually abstinent or delaying 
initiation of sexual activity, decreasing the number of 
sexual partners, and using condoms consistently and 
correctly if sexually active.
t  hiv testing: Encouraging hiv testing is critical for 
prevention — people who know their hiv status are more 
likely to protect themselves and others from infection.
t  Diagnosis and Treatment of Other stds: Infection 
with other sexually transmitted diseases (stds) such 
as gonorrhea increases the risk of hiv transmission, 
and prompt diagnosis and treatment of stds can help 
reduce hiv risk.
Preventing Blood Borne Transmission
t  Harm reduction for injection drug users: Harm 
reduction programs that provide clean needles and 
syringes have been proven to be effective in reducing the 
risk of hiv transmission among injection drug users, 
without contributing to an increase in drug use.
t  Blood supply safety: Routine screening of the blood 
supply can virtually eliminate the risk of hiv transmission 
through donated blood.
t  Infection control in health care: Countries that require 
health workers to adopt “universal precautions” such as 
wearing gloves and masks have succeeded in making 
hiv transmission extremely rare in health care settings.
Preventing Mother-to-Child Transmission
t  Antiretroviral drugs: The inexpensive antiretroviral 
drug nevirapine can reduce the risk that an hiv-
infected pregnant woman will transmit hiv to 
her child by nearly 50 percent. Combinations of 
antiretrovirals can reduce the risk even further.
t  Breastfeeding alternatives: The chance of an hiv-
infected mother transmitting hiv to her newborn 
increases by up to half with prolonged breastfeeding, 
and hiv-infected mothers should have access to 
breastfeeding alternatives.
t  Caesarean delivery: Caesarean delivery significantly 
reduces the risk of mother-to-child hiv transmission.
Supportive Policies
hiv prevention is most effective when it is supported by 
strong and visible political leadership, and by policies that 
address the root causes of vulnerability to hiv, including:
t  Anti-stigma measures that prevent discrimination 
against people with hiv and vulnerable groups
t Gender-equality initiatives, including programs   
     to enhance women’s education and economic 
independence, and laws to combat 
sexual violence and trafficking
t  Involvement of communities 
and hiv-infected individuals in 
educating people about hiv, and 
in developing, implementing, and 
evaluating prevention programs
t  Visible political leadership that 
prioritizes a comprehensive 
response to the hiv/aids epidemic, 
including prevention, treatment, 
and care
5
expanding access to existing  
hiv prevention approaches
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FIGURE 3. Access to Existing hiv Prevention Methods
A range of promising new hiv prevention approaches are 
currently under investigation. If shown to be effective, 
these new tools and strategies could help avert millions 
of new infections, and have a substantial impact on the 
course of the hiv/aids epidemic. They include:
t Male circumcision
t Cervical barriers
t Pre-exposure prophylaxis with antiretrovirals
t Herpes suppression
t Microbicides
t hiv vaccines
Some of these new prevention methods — including male 
circumcision, cervical barriers, pre-exposure prophylaxis 
with antiretrovirals, and herpes suppression — could 
potentially be shown to be effective within the next few 
years. While the successful development of prevention 
methods such as microbicides and vaccines is likely to 
take longer, important progress is being made on these 
fronts as well.
Many of these new hiv prevention methods could 
be particularly beneficial for women, who represent 
approximately one-half of hiv infections globally, and 
nearly 60 percent of people living with hiv in sub-
Saharan Africa.8 Physiologically, women are more 
vulnerable to hiv infection than men. In addition, many 
women have difficultly negotiating abstinence and 
condom use with male partners, especially in countries 
where women lack legal rights and are economically 
dependent on men.9
It is important to note that there is no “magic bullet” 
for hiv, and that none of these new hiv prevention 
methods is likely to be 100 percent effective. All would 
require the continued use of current prevention methods 
that have already been proven to be effective — including 
behavior change programs, condoms, hiv testing, and 
treatment of other sexually transmitted diseases.10 As 
discussed in section 3 of this report, it is also essential 
to ensure that risk behavior does not increase with the 
introduction of new prevention methods.
This section describes the state of research into new 
prevention tools and strategies. Figure 4 on page 7 
summarizes current efficacy trials of new hiv prevention 
methods.
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i.  hiv prevention research: 
state oF the science
new hiv prevention 
approaches in 
development
t  Male circumcision: Observational studies have 
shown that countries with high rates of male 
circumcision — removal of the foreskin of the 
penis — have lower hiv infection rates.
t  Cervical barriers: Cervical barriers, such as the 
diaphragm, cover the cervix, the site where most  
hiv infections in the female genital tract are  
believed to occur.
t  Pre-exposure prophylaxis with antiretrovirals: 
Antiretroviral drugs, which improve the health of  
hiv-infected people, may also prevent hiv infection.
t  Herpes suppression: Data suggest that infection  
with hsv-2, the primary cause of genital herpes, 
increases the risk of hiv acquisition and transmission. 
Suppressing herpes with the inexpensive, off-patent 
drug acyclovir may reduce hiv risk.
t  Microbicides: Microbicides are topical substances 
applied to the vagina or rectum to potentially  
prevent hiv infection.
t  hiv vaccines: Preventive vaccines enhance the 
body’s immune defenses, enabling the immune 
system to fight off diseases that it cannot naturally 
control.
Source: usaid et al., 00
FIGURE 4. current efficacy trials of  
new hiv prevention methods
Prevention Method Trial Sites and Participants Primary Sponsors and Funders
Male Circumcision Kenya — 2,500 men University of Illinois, U.S. National  
  Institutes of Health (nih) 
 Uganda — 5,000 men Johns Hopkins University, nih 
 Uganda —1,361 men and 7,000 women Columbia University,  
   Gates Foundation 
Cervical Barriers South Africa and Zimbabwe —  University of California at San Francisco, 
   Female diaphragms 5,045 women Gates Foundation
Pre-Exposure Prophylaxis with Antiretrovirals
   Tenofovir Thailand —1,600 injection drug users U.S. Centers for Disease Control and  
  Prevention (cdc)
   Tenofovir plus  Botswana —1,200 men and women cdc 
   emtricitabine
 Peru —1,400 men who have sex with men nih
Herpes Suppression Peru, South Africa, Zambia, Zimbabwe,  University of Washington, nih 
 and U.S. — 3,277 men and women 
 Botswana, Kenya, Rwanda, South Africa,  University of Washington, 
 Tanzania, Uganda, and Zambia —  Gates Foundation 
 3,000 male-female couples in which one  
 partner is infected with hiv and hsv-2
Microbicides
   C31G (Savvy) Nigeria — 2,142 women Family Health International (fhi),  
  U.S. Agency for International  
  Development (usaid)
   Carbopol 974p  Malawi, South Africa, Tanzania, Zambia,  nih 
   (BufferGel) Zimbabwe, and U.S. — 3,220 women
   Cellulose sulfate Nigeria — 2,160 women fhi, usaid 
 Benin, Burkina Faso, India, South Africa,  conrad, Gates Foundation, usaid 
 and Uganda — 2,574 women
   Naphthalene sulfonate  Same as Carbopol trial (see above) nih 
   
(PRO2000)
 South Africa, Tanzania, Uganda,  U.K. Medical Research Council,  
 Zambia, and Zimbabwe —  U.K. Department for International 
 10,000 women  Development 
  PC-515 (Carraguard) South Africa — 6,299 women Population Council,  
  Gates Foundation, usaid 
HIV Vaccines
  gag, pol, nef in adenovirus Australia, Brazil, Canada, Dominican Republic, Haiti, Merck & Co., nih 
  type 5 (MrkAd5) Jamaica, Peru, and U.S. — 3,000 men and women
  env, gag, pol in canarypox  Thailand — 16,000 men and women Thailand Ministry of Public Health, 
  + gp120 (alvac + aidsvax)  nih, U.S. Military hiv Research Program 
male circumcision
Male circumcision — removal of the foreskin of the penis — may 
reduce the risk of hiv acquisition and transmission during 
sexual intercourse.
Theoretical Basis
Observational studies have long noted that, on average, 
countries with high rates of male circumcision have 
lower hiv infection rates.11 Circumcision may reduce 
hiv risk because the mucosal surface of the foreskin 
of the penis contains Langerhans cells that are highly 
susceptible to hiv infection.12 Circumcision may reduce 
hiv risk directly, or have an indirect effect by preventing 
other sexually transmitted diseases that facilitate hiv 
acquisition and transmission.
Status of Research
In 2005, French and South African researchers announced 
encouraging results from the first randomized clinical trial 
of the efficacy of male circumcision for hiv prevention. 
The investigators reported that men who were randomly 
assigned to receive circumcision had a 60 percent lower 
risk of subsequently acquiring hiv infection from female 
partners than men randomized to the control arm of the 
study, who were offered circumcision after the trial ended. 
The trial was conducted among 3,274 men in a community 
near Johannesburg, South Africa, and the findings have 
generated hope that circumcision could be an important 
new hiv prevention strategy.13
Three efficacy trials of male circumcision are underway 
in Kenya and Uganda, and unaids and other international 
health agencies have emphasized the importance of 
waiting for these results before recommending widespread 
adoption of male circumcision for hiv prevention.14 The 
trials in Kenya and Uganda involve more than 8,000 men, 
and are likely to offer important insights regarding the 
applicability of male circumcision in different settings. For 
example, the Uganda trials involve a broader age range 
(15–49) than the South Africa and Kenya trials (18 –24), and 
use a different circumcision procedure (sleeve circumcision 
versus the forceps-guided procedure used in South Africa 
and Kenya). Results from these trials are expected in 2007.
In addition to studying the efficacy of male circumcision 
for preventing female-to-male hiv transmission, one of the 
trials in Uganda is following 7,000 women — including 
approximately 4,000 female partners of male participants 
in the circumcision trials — to determine if circumcising 
men also reduces the risk of hiv transmission from  
men to women, as suggested by observational data.15  
The findings among women in the Uganda trial could 
have important public health significance, because most 
hiv infections in women are the result of male-to-female 
transmission of the virus.
Potential Prevention Impact
Used in combination with other hiv prevention methods, 
male circumcision could have a substantial impact on 
reducing hiv acquisition and transmission. One modeling 
study predicts that widespread implementation of male 
circumcision could avert 2 million new hiv infections 
over the next 10 years in sub-Saharan Africa, and a further 
3.7 million new infections over the 10 years after that (see 
figure 5 for South Africa projections).16 Circumcision is 
also potentially important as a prevention option because it 
is a one-time intervention that could offer life-long benefit. 
Research indicates that circumcision would be acceptable 
to men in Africa: a study of adult males circumcised 
in Kenya found that 99 percent were satisfied with the 
procedure, as were their female partners.17
When performed by a trained practitioner, male 
circumcision is a safe procedure (typically defined as 
resulting in surgical complications in fewer than 2 percent 
of cases), and analgesia effectively mitigates pain. 
However, as noted in section 3 of this report, concerns 
have been raised about the safety of circumcision 
procedures performed by medical practitioners or 
traditional healers who have not been properly trained, 
underscoring the importance of coupling future 
introduction of male circumcision for hiv prevention 
with strong training and quality assurance initiatives.
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cervical barriers
Cervical barriers such as the diaphragm and cervical caps are 
currently used with spermicides as contraceptives. Made of 
latex or silicone, they are inserted into the vagina to cover the 
cervix and serve as a barrier against sperm.
Theoretical Basis
Research suggests that most hiv infections in the 
female genital tract occur in the cervix and endocervix.18 
Cervical barriers such as diaphragms cover the cervix, 
and by doing so may significantly reduce women’s risk 
of becoming 
infected with 
hiv. In addition, 
cervical barriers 
may prevent hiv 
by preventing 
infection with 
other sexually 
transmitted 
diseases that 
facilitate hiv 
transmission.
Status of Research
A clinical trial in South Africa and Zimbabwe is testing 
the efficacy of the latex diaphragm used with a non-
contraceptive lubricant gel for preventing male-to-female 
hiv transmission. The trial involves 5,045 women and is 
comparing use of the diaphragm plus condoms with use 
of condoms alone. Results are expected in 2007.
Potential Prevention Impact
If proven to be effective for hiv prevention, cervical 
barriers such as diaphragms would have a number 
of distinct advantages. Diaphragms are inexpensive, 
reusable, and already approved and available for 
pregnancy prevention. In addition, diaphragms can be 
inserted in advance of sexual activity, left in place up to 
24 hours, and potentially used without the knowledge 
of the woman’s sexual partner. Studies in Zimbabwe 
suggest that the diaphragm is accepted among women 
at risk for hiv,19 and women and their male partners 
prefer the diaphragm to other female-initiated prevention 
methods such as the female condom.20 
Cervical barriers such as diaphragms could also 
potentially be used to deliver microbicides for hiv 
prevention (see discussion of microbicides on page 12).
pre-exposure 
prophylaxis with 
antiretrovirals
Antiretroviral drugs, which improve the health of hiv-infected 
people, may also prevent hiv infection.
Theoretical Basis
Antiretroviral drugs, which have improved the health 
and prolonged the lives of people infected with hiv, 
are currently also used to prevent some forms of hiv 
transmission. Timely administration of antiretrovirals 
reduces the risk of hiv transmission from hiv-infected 
mothers to their newborns,21 and to health care workers 
with occupational percutaneous exposure to hiv (i.e., by 
needle stick), if administered shortly after exposure.22 It 
is hypothesized that daily pre-exposure administration of 
antiretrovirals to hiv-uninfected individuals may prevent 
hiv infection by disabling or interfering with hiv within 
the initial period after an individual is exposed to it.
Status of Research
In recent years, researchers have begun studying the 
antiretroviral drug tenofovir, taken as a once-daily pill, 
as a potential new method to prevent hiv infection in 
high-risk individuals, an approach known as pre-exposure 
prophylaxis, or prep. Tenofovir is approved for the 
treatment of hiv infection; it is especially long-lasting 
in the body, unusually slow to cause hiv to develop 
resistance, and rarely causes serious side effects.23 
In monkey studies, tenofovir has shown promise in 
preventing infection with hiv-like viruses,24 although 
other animal studies have suggested that tenofovir’s 
effectiveness may decrease over time.25
Researchers are also beginning to test a combination 
pill containing tenofovir plus emtricitabine.26 A monkey 
study with the combination regimen showed that it 
provided strong protection against hiv-like infection.27
Over the past few years, a number of clinical trials have 
been initiated to evaluate the safety and efficacy of pre-
exposure prophylaxis with antiretrovirals for hiv prevention:
t  Safety: Data on the safety of administering tenofovir to 
hiv-uninfected people has been collected from trials 
involving more than 900 women in Ghana, Cameroon, 
and Nigeria. An additional safety trial is ongoing 
among men in the United States.
t  Efficacy: Clinical trials to assess the efficacy of daily  
administration of tenofovir, or tenofovir plus emtricitabine, 

Diaphragm and lubricant gel
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research to improve existing  
prevention methods
In addition to efforts to develop new hiv prevention 
methods, researchers are exploring ways to improve the 
prevention impact of existing approaches:
t  Next-generation female condoms: The fc® female 
condom was developed in the 0s by the Female 
Health Company and provides an alternative to male 
condoms for the prevention hiv and other sexually 
transmitted diseases.33 However, the product, which 
is made of polyurethane, has not been widely used 
because of its relatively high cost. The Female Health 
Company is developing a new female condom made of 
synthetic latex (nitrile polymer), which is expected to 
be considerably less expensive. Other organizations, 
including the Program for Appropriate Technology in 
Health, are also working on other models of female 
condoms. The World Health Organization (who) is 
currently reviewing data on the new female condom  
to determine its suitability for use in hiv prevention. 
The redesign of the female condom could also facilitate 
its use for hiv prevention during anal sex, for both 
heterosexual couples and men who have sex with men.34
t  Treatment of drug addiction: Methadone is currently 
used to treat addiction to opiate drugs such as 
heroin, and has been shown to reduce the risk of hiv 
transmission through injection drug use. Although 
roughly three-quarters of people who initiate methadone 
maintenance therapy respond well, the intervention 
does not suit all patients with opioid dependence.35 
Researchers are testing buprenorphine in China and 
Thailand as an alternative to methadone for treating 
heroin addiction and reducing hiv risk. The U.S. 
Food and Drug Administration has already approved 
buprenorphine for treatment of heroin addiction when 
administered by a physician, and buprenorphine is also 
prescribed in several European countries. who has 
added both methadone and buprenorphine to its List  
of Essential Medicines.
t  Improved mother-to-child prevention strategies: 
Researchers are studying ways to improve the 
effectiveness of current strategies for preventing 
mother-to-child transmission. For example, a clinical 
trial in Africa will assess an extended regimen of the 
antiretroviral drug nevirapine to reduce the risk of 
hiv transmission to newborns during breastfeeding. 
Other clinical trials will test a range of antiretrovirals 
for mother-to-child prevention. At the same time, an 
important shortcoming of mother-to-child prevention 
programs is the fact that they reach fewer than 0 
percent of women who could potentially benefit from 
them.36 who has identified research into the barriers to 
providing access to existing mother-to-child prevention 
programs as a top priority.
t  Improved behavior change strategies: Researchers 
are studying ways to strengthen behavior change 
for hiv prevention are being conducted in three 
countries — Botswana, Peru and Thailand. The trials will 
enroll approximately 4,200 participants from a number of 
groups at high risk for hiv, including injection drug users, 
men who have sex with men, and high-risk women. The 
first results on the efficacy of pre-exposure prophylaxis for 
hiv prevention could be available by 2007 or 2008.
Research is in earlier stages for the potential prevention 
application of other antiretroviral agents, including new 
classes of drugs that are also being developed as potential 
hiv treatments.
Potential Prevention Impact
If shown to be effective, pre-exposure prophylaxis with 
antiretrovirals could be an important new prevention 
method for people at high risk for hiv infection. A modeling 
study sponsored by aids Partnership California concluded 
that providing prep to high-risk groups such as men who 
have sex with men, injection drug users, and high-risk 
women could quickly reduce the rate of new hiv infections, 
depending on the level of prep’s efficacy, and the percentage 
of people at risk who received the intervention.28
While prep is likely to be more expensive than other new 
hiv prevention methods under investigation, if found to be 
highly efficacious, studies suggest it could nonetheless be a 
cost-effective prevention method for high-risk groups, when 
used in combination with other prevention methods.29
One potential concern regarding pre-exposure 
prophylaxis is resistance. Any resistance developed to 
antiretrovirals such as tenofovir when used for prevention 
could limit the usefulness of the drugs for later hiv 
treatment. Several of the ongoing or planned trials are 
examining this important question.

herpes 
suppression
Data suggest that infection with herpes simplex virus type 2 
(hsv-2), the primary cause of genital herpes, increases the  
risk of hiv acquisition and transmission. Suppressing hsv-2 
with the inexpensive, off-patent drug acyclovir may reduce 
hiv risk.
Theoretical Basis
An hiv-uninfected individual is up to three times more 
likely to contract hiv infection during sexual intercourse 
if he or she is infected with hsv-2.30 In addition, because 
hsv-2 appears to accelerate hiv replication and shedding, 
hiv-infected individuals may be more likely to transmit 
hiv if they are also infected with hsv-2.31
Researchers aim to determine whether the drug 
acyclovir, which suppresses hsv-2, can help reduce the 
risk of hiv transmission.* Acyclovir is safe and well 
tolerated, and slow to cause hsv-2 to develop resistance  
in both hiv-infected and hiv-uninfected people.32
Status of Research
Two clinical trials are evaluating the efficacy of 
suppressing hsv-2 with acyclovir as an hiv prevention 
strategy. The first trial involves 3,227 men and women 
who are infected with hsv-2 but uninfected with hiv in 
interventions that encourage people at high risk for 
hiv infection to reduce risk behavior. For example, a 
clinical trial in Thailand and the United States will test 
a peer-based hiv prevention program for injection drug 
users. In the trial, injection drug users will be given a 
four-week training course to learn skills for educating 
other drug users about ways to reduce the risk of hiv 
acquisition and transmission.
t  New “prevention for positives” strategies: Because so 
few people in developing countries are aware of their 
hiv status,37 prevention programs have often relied 
on general messages that implicitly assume that all 
individuals are hiv-uninfected — an approach that 
may be limiting the effectiveness of hiv prevention 
efforts. Although a positive hiv test result typically 
prompts hiv-infected people to avoid transmitting hiv 
to others,38 evidence in developed countries indicates 
that a notable share of people with hiv infection 
have difficulty implementing and sustaining safer 
behavior.39 In recent years, who, the International 
Planned Parenthood Federation, and the U.S. Centers 
for Disease Control and Prevention, among others, have 
begun examining behavior change strategies tailored 
specifically for people living with hiv.40
t  Antiretroviral therapy to reduce the risk of hiv 
transmission: Antiretroviral therapy reduces viral 
load in hiv-infected individuals, and studies have 
shown that lower viral load is strongly associated 
with lower transmission risk.41 On this basis, it has 
been hypothesized that appropriate therapeutic 
administration of antiretrovirals may reduce the 
infectiousness of people with hiv and their likelihood 
of transmitting the virus to others. Currently, ,00 hiv-
discordant couples are being enrolled in a six-country, 
seven-year clinical trial to assess whether administering 
combinations of antiretrovirals to hiv-infected 
individuals reduces the risk of hiv transmission. The 
trial is also assessing whether the prevention impact of 
antiretroviral therapy can be enhanced by administering 
antiretrovirals to hiv-infected people earlier than would 
currently be medically indicated.
t  Improving the safety of health care injections: Unsafe 
injections and blood-draws in health care settings 
account for an estimated 5 percent of new infections 
worldwide.42 In , who, unicef, and the United 
Nations Population Fund issued a joint statement 
identifying the inexpensive “auto-disable” syringe 
as the “equipment of choice” for routine and mass 
immunization.43 However, as of 00,  percent of 
developing countries did not use auto-disable syringes 
in their immunization programs.44 In addition to 
ensuring universal adoption of auto-disable syringes, 
research efforts in both public and private sectors 
continue to focus on other methods to improve 
injection safety.
*  It is important to note that even if herpes suppression is not 
proved efficacious for hiv prevention, expanded access to 
acyclovir treatment could significantly decrease the global 
burden of herpes.
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Africa, Latin America, and the United States; this study 
will help determine whether hsv-2 suppression decreases 
the risk of hiv acquisition. The second trial involves 3,000 
hiv-discordant couples in Africa in which one partner is 
infected with both hiv and hsv-2 and the other is not hiv-
infected. This study will help determine whether hsv-2 
suppression decreases the likelihood that people infected 
with hiv will transmit it to others. Results are expected in 
2007 for the trial among hiv-uninfected people, and in 
2008 for the trial among hiv-discordant couples.
Potential Prevention Impact
If proven to be effective and used in combination with other 
prevention methods, suppression of hsv-2 with acyclovir 
could significantly strengthen efforts to reduce sexual hiv 
transmission. In some parts of southern Africa, up to 70 
percent of adults are infected with hsv-2,45 and a recent four-
city study in Africa linked hsv-2 with more than one-third of 
all new hiv infections over a 15-year period (see figure 6).46
From a cost perspective, acyclovir is an attractive 
prevention option. Because its patent has expired, 
the drug is inexpensive and already available in many 
developing countries.
microbicides
Microbicides are topical substances designed to be applied to 
the vagina or rectum to prevent hiv infection. Some vaginal 
microbicides may also prevent pregnancy.
Theoretical Basis
Microbicide candidates currently in research and 
development are designed to operate in a variety of ways 
to prevent hiv infection. These include:
• Disabling hiv
•  Providing a barrier between hiv in semen and vaginal 
or rectal tissue
•  Interfering with the process by which hiv enters cells 
and establishes infection
•  Strengthening the body’s natural defenses against hiv 47
Status of Research
As of mid-2006, the microbicide research pipeline included 28 
candidate products.48 Microbicide candidates can be divided 
into two groups, first- and second-generation candidates.
First-generation microbicide candidates: Five microbicide 
candidates — all formulated as clear, colorless gels —  
are furthest along in development and are being tested in 
large-scale clinical trials for efficacy:
•  C31G (Savvy) is a surfactant compound designed to 
disable hiv by breaking down its outer membrane. 
The product is being tested in a clinical trial involving 
2,142 women in Nigeria. C31G may also protect against 
pregnancy.
•  Carbopol 974p (BufferGel) is a buffering compound 
designed to function as a barrier between hiv in semen 
and vaginal tissue. It is also designed to maintain the 
vagina’s acidity in the presence of semen, which may 
help kill or disable hiv. Carbopol is being tested in 
a clinical trial involving 3,220 women in five African 
countries and the United States. Carbopol may also 
prevent pregnancy.
•  Cellulose sulfate is an attachment inhibitor that aims to 
prevent hiv from attaching to cells in the vaginal wall. 
A 2,160-participant trial has begun in Nigeria, and a 
second trial among 2,574 women has started in four 
African countries and India. Cellulose sulfate may also 
prevent pregnancy.
•  Naphthalene sulfonate (pro2000) is similar to cellulose 
sulfate, and is designed to prevent infection by binding 
to hiv and interfering with its ability to attach to and 
1990 1995 20052000
N
um
be
r 
of
 p
eo
pl
e 
liv
in
g 
w
ith
 h
iv
 (
m
ill
io
ns
)
year
0
10
20
30
40
50
= Range around estimate
 2030 2000 2005 2010 2015 2020
A
nn
ua
l r
at
e 
of
 n
ew
 h
iv
 in
fe
ct
io
ns
year
0%
1%
2%
3%
If all men in South Africa are circumcised by 2015
(Assumes male circumcision is 60 percent effective in preventing
 both female-to-male and male-to-female hiv transmission)
If  he proportion of circumcised men remains constant
0 5 1510
Pe
rc
en
t o
f n
ew
 h
iv
 in
fe
ct
io
ns
 a
tt
ri
bu
ta
bl
e 
to
 h
sv
-2
 Years after first hiv infection in city
10%
0%
20%
30%
40%
50%
Cotonou, Benin
Yaounde, Cameroon
Ndola, Zambia
Kismu, Kenya
  -- We don't need to show 1980 - 2000 on the x-axis, 
so you can stretch out 2000 - 2030 to cover the whole space of the graph.
    -- Please add tick marks to the x-axis, and center the year 
labels under each tick mark (same as you did for the x-axis in figure 3).
FIGURE 6. Four-City Study: Herpes Infection Fuels hiv Spread
Source: Freeman et al., 005

enter cells. The candidate is being tested in the same 
3,220-participant trial as Carbopol (see above), and a 
separate trial is underway among approximately 10,000 
participants in five African countries.
•  pc-515 (Carraguard) is also an hiv attachment inhibitor. 
Its active ingredient, carrageenan, is derived from 
seaweed. A clinical trial is underway in South Africa 
involving 6,299 women.
The first results from efficacy trials of first-generation 
microbicide candidates could potentially be available  
in 2008.
Second-generation microbicide candidates: While the 
microbicide candidates above are in late-stage trials and 
could potentially be shown to be effective within the next 
five years, there is growing interest in second-generation 
microbicide approaches that are approximately 10 years 
away from completing testing. Second-generation 
microbicide candidates specifically target hiv or molecules 
of the cells it infects, and some of these microbicide 
approaches involve using existing or new classes of 
antiretroviral compounds as microbicides.49
Researchers are also investigating new ways of 
formulating microbicides, such as using them in vaginal 
rings or cervical barriers.50 In addition, although most 
development efforts have concentrated on vaginal 
microbicides, a number of early research projects are 
advancing the development of rectal microbicides, which 
could reduce the risk of hiv transmission during anal sex.51
Potential Prevention Impact
A modeling study from the London School of Hygiene and 
Tropical Medicine estimated that a 60 percent effective 
microbicide could avert 2.5 million new hiv infections in 
low- and middle-income countries over three years.52 A 
separate modeling project concluded that a microbicide 
that is 60 percent effective against hiv and other stds could 
prevent more than one-third of new hiv infections that are 
projected to occur over four years in a district in northern 
Karnataka, India, where infection is migrating from high-
risk groups to the broader population (see figure 7).53
Other studies have predicted that even a microbicide 
with a relatively low effectiveness rate could prevent 
9 percent of new infections over four years in a high-
prevalence neighborhood of Johannesburg, South Africa, 
and nearly 40 percent of new infections projected in a 
lower-prevalence setting in Benin.54
Like many of the other new hiv prevention methods 
in development, microbicides would be female-initiated, 
and may be able to be used by women without requiring 
the cooperation of male partners. Developers of potential 
microbicides have conducted extensive research into 
the acceptability of their products, and evidence to date 
indicates that women and men in both developing and 
developed countries are interested in using microbicides.  
Further research is needed to identify the specific product 
characteristics that would be most acceptable to women 
and men.55
hiv vaccines
Preventive vaccines enhance the body’s immune defenses, 
enabling the immune system to fight off diseases that it cannot 
naturally control.
Theoretical Basis
The ultimate goal for an hiv vaccine is to prevent hiv 
infection. Scientists have identified rare individuals 
whose immune systems appear to have a natural ability  
to resist hiv infection, a finding that provides clues for 
the design of an effective vaccine.
However, an hiv vaccine that does not prevent 
infection but, in the event of infection, suppresses the 
amount of virus circulating in the body could also have 
a substantial impact. Such a vaccine would work much 
like antiretroviral drugs that lower viral load in order to 
keep people with hiv healthy, except that a vaccine would 
stimulate the immune system to do this, rather than 
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requiring daily doses of medicine. An hiv vaccine that 
lowered viral load may also reduce hiv transmission.
Status of Research
Developing an effective hiv vaccine has proven to be a 
highly complex scientific challenge, and most research 
is at an early stage.56 To date, traditional vaccine designs 
have not worked for hiv, in part because the virus is 
able to evade the immune system by rapidly mutating. 
Some experimental vaccines have been shown to protect 
monkeys from hiv-like viruses, although the results have 
not yet been replicated in humans.57
The one hiv vaccine candidate to complete the full course 
of clinical trials was found to be ineffective.58 More than 30 
other hiv vaccine candidates are currently in clinical trials, 
including two vaccine candidates in advanced efficacy or 
proof-of-concept trials (see figure 4 on page 7).59
Most experts predict that it will be 10 years or more before 
an hiv vaccine is shown to be effective. A major challenge 
facing researchers is that it is likely that an effective vaccine 
will need to stimulate the immune system’s two main arms, 
called humoral immunity (broadly neutralizing antibodies) 
and cellular immunity. Most hiv vaccine candidates 
currently being tested are designed only to stimulate cellular 
immunity, and research is in the very early stages  
funding for hiv prevention research
Only a small percentage of total global spending on 
biomedical research and development focuses on hiv/
aids and other diseases that primarily affect developing 
countries.63 Funding for research on new hiv prevention 
methods is inadequate.
The best available information on funding for hiv 
prevention research is for microbicide and vaccine 
development (see figure ):64
t Microbicide funding: The hiv Vaccines and Microbicides 
Resource Tracking Group estimates that a total of 
$ million was invested worldwide in microbicide 
development in 00. The public sector was the main 
source of this funding, accounting for  percent of 
total funding. The United States provided nearly three-
quarters of public sector funding — largely through the 
National Institutes of Health and the U.S. Agency for 
International Development. European governments and 
the European Commission provided roughly one-quarter 
of public sector funding in 00.
t  hiv vaccine funding: In 00, an estimated total of  
$6 million was spent on hiv vaccine development, 
of which  percent was public sector funding. U.S. 
government agencies provided a significant share  
(6 percent) of this funding.
Although current levels of funding for microbicide and 
vaccine development represent substantial increases 
over previous years — public sector investments in both 
microbicide and hiv vaccine development doubled 
between 000 and 00 — far more resources are needed. 
The International Partnership for Microbicides (ipm) has 
called for an additional $0 million to be invested in 
microbicide development annually, and the Global hiv 
Vaccine Enterprise has urged an additional $500 million 
annually to fully fund hiv vaccine development.65
Experience thus far underscores the critical need for 
increased financing for prevention research. In some 
cases, large-scale efficacy trials for new prevention 
approaches have proven to be significantly more expensive 
than originally anticipated. As this report describes in 
section , large prevention trials require substantial 
outlays for pre-trial epidemiological and behavioral 
studies, involve time-consuming efforts to enroll sufficient 
participants, and require close monitoring by well-trained 
clinical and non-clinical staff. The emergence of effective 
new prevention methods that may need to be included as 
part of the standard package of prevention interventions 
offered to all trial participants could further increase the 
cost of future prevention trials by requiring the enrollment 
of significantly larger numbers of trial participants.
Increasing Private Sector Investments
Private industry has generally been reluctant to invest 
in new health products intended for primary use in 
developing countries because of the concern that these 
products are unlikely to obtain a return on investment.
While public and philanthropic financing has a played 
a vital role in advancing research on new prevention 
methods, it cannot replace the unique contributions of 
the private sector. Expertise regarding development and 
licensure of new health products resides largely with 
the private sector — failing to capitalize on the essential 
know-how of private industry will inevitably slow efforts to 
develop new methods to prevent hiv transmission.66
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to identify vaccine candidates capable of stimulating broadly 
neutralizing antibodies.60
Recently, a number of leading hiv vaccine research 
agencies and funders formed a cooperative alliance to 
accelerate progress in developing an hiv vaccine. The Global 
hiv Vaccine Enterprise seeks to overcome the major scientific 
challenges to developing an hiv vaccine by bringing new 
collaboration, strategic focus, and resources to the field.61
Potential Prevention Impact
A preventive vaccine is the best long-term hope to control 
the global hiv epidemic. Vaccines have been successfully 
developed for other serious viral diseases — including polio 
and hepatitis B — and have been critical to controlling 
these diseases.
For hiv, a number of modeling studies suggest that 
even a partially effective vaccine could have a substantial 
impact on the course of the epidemic, although — like 
other prevention approaches — it would need to used in 
combination with other proven methods. For example, a 
modeling study by the World Bank found that a 50 percent 
efficacious hiv vaccine could reduce hiv infection rates by 
up to 60 percent in developing countries, provided that it 
was delivered to a majority of adults at risk.62
A number of public policy measures have been proposed 
to encourage greater private sector engagement in research 
and development for hiv/aids and other diseases that 
primarily affect developing countries. These include:
t  Direct financing: The public and philanthropic sectors can 
provide direct financing to private companies to conduct 
research. In exchange, the companies agree to make any 
resulting products available at affordable prices in low-
income countries. This approach is being pursued by a 
number of public-private partnerships, such as ipm and  
the International aids Vaccine Initiative.
t  Patent extensions: The Project Bioshield II legislation 
introduced in 005 in the U.S. Congress proposed 
that companies that successfully develop new hiv 
prevention tools could extend the patent on any other 
product in their portfolio.
t  Predictable markets: Governments and donors could 
make legally binding agreements to pay a specific 
price for a specific quantity of a product, should it 
be successfully developed.67 For example, the G- is 
exploring “advance purchase commitments” to help  
spur companies to develop new tools to fight major 
global health problems such as malaria.
These approaches are designed to generate greater  
private sector investment in biomedical research by 
reducing uncertainties in the market for new health 
technologies in developing countries. Other non-financial 
reforms — such as improved demand forecasting, strong 
expressions of political commitment by developing 
country leaders to put new technologies to use, 
and measures to strengthen health service delivery 
systems — are discussed in section  of this report.
FIGURE 8 . Spending on Microbicide and hiv Vaccine Development, 2000 – 2004
 2000 2001 2002 2003 2004
Microbicides
Public sector 36 62 81 90 124
Philanthropic sector 29 3 25 17 18
Total microbicides 65 65 106 107 142
hiv Vaccines
Public sector 307 359 436 532 602
Philanthropic sector 20 7 112 15 12
Private sector*     68
Total hiv vaccines 327 366 548 547 682
US$ MILLIONS
* Private sector spending figures available only for hiv vaccines in 2004  Source: hiv Vaccines and Microbicides Resource Tracking Group, 2005
The proper design and conduct of clinical trials is essential 
to the development of any new health tool or strategy.68
Clinical trials can be complicated and expensive. 
This is especially true for hiv prevention trials, which 
often require thousands of trial participants, who must 
be followed for up to several years in order to reliably 
detect whether the prevention method being studied is 
effective in reducing hiv transmission. Because it is critical 
to test new health tools and strategies under the conditions 
in which they will ultimately be used, many hiv prevention 
trials are conducted in developing countries where the need 
is most acute. This can increase their complexity, since 
clinical trials infrastructure in many developing countries 
often needs to be established in order to conduct a trial.
As a result of the expanding pipeline of new 
prevention methods and the increasing complexity of 
trials, substantial additional clinical trials capacity will 
be needed to prevent delays in testing new prevention 
methods. New ways of doing business are also needed 
to prioritize testing of the prevention methods that offer 
the greatest public health promise, and to promote 
collaboration among researchers to ensure the optimal 
use of scarce trial resources.
This section examines the following issues related 
to accelerating the pace of hiv prevention research, 
and ensuring that hiv prevention trials are conducted 
properly:
t  Creating substantial additional clinical trials capacity 
that can be readily adapted for testing a range of new 
prevention methods, and identifying populations to 
participate in trials
t  Resolving critical issues pertaining to the ethical 
conduct of hiv prevention trials
t  Engaging affected communities as key partners in 
prevention research
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t  Clinical trials capacity: To avoid delays in testing 
promising new hiv prevention methods, leading trial 
sponsors, governments, and international donors should 
make significant new investments in increasing global 
capacity for hiv prevention trials. There is also a need to 
strengthen regulatory capacity to review trial protocols.
t  Trial design: Researchers should develop improved 
models for accurately estimating the number of 
participants needed for hiv prevention trials, and create 
innovative trial designs that could reduce the number of 
participants needed to obtain valid results.
t  Coordination among trial sponsors: Trial sponsors and 
international agencies should develop clear criteria 
to prioritize prevention methods for clinical trials. 
Sponsors should share data and information, and 
ensure that study sites can be adapted as needed and 
appropriate to test different prevention interventions.
t  Ethical issues: Trial sponsors and international agencies 
should convene a broadly inclusive panel of experts 
to develop formal guidance on ethical issues in hiv 
prevention research that have recently emerged and are 
not addressed by existing guidance.
t  Community engagement: Investigators and sponsors 
of hiv prevention trials should ensure meaningful 
involvement of local communities in trial design and 
conduct.
accelerating hiv prevention research—
key recommendations

clinical trials 
capacity
Global capacity to conduct hiv prevention clinical trials falls 
far short of what will be needed to expedite the development 
and testing of promising new prevention approaches 
over the coming years. Unless immediate steps are taken 
to increase the number of sites prepared to conduct hiv 
prevention trials, the world could soon face a situation where 
there is a pipeline of promising new prevention methods 
ready for trials, but inadequate capacity to test them.
Developing Additional Clinical Trial Sites
As research on new hiv prevention methods advances, 
the need for additional sites to conduct clinical trials will 
increase sharply. For example, in addition to the five 
microbicide candidates currently in large-scale clinical 
trials, a number of other candidates are in earlier stages 
of trials, and still more candidates are undergoing pre-
clinical investigation. Key issues include:
t Recruitment and retention of potential participants: 
Fully testing just one new hiv prevention method for 
safety and effectiveness typically requires thousands 
of trial participants. Current efficacy trials of new 
hiv prevention approaches will require a total of 
approximately 80,000 participants, with most of this 
capacity needed in developing countries.
t  Confirmatory and bridging trials: Although a number 
of large-scale trials of new hiv prevention methods 
are underway, and some are already fully enrolled, 
these trials are unlikely to be the definitive word on the 
effectiveness of these tools and strategies. New health 
interventions typically must be tested in multiple large-
scale trials, to confirm the results and ensure they are 
accurate and broadly applicable.69 For example, in a 
review of 39 heavily cited randomized clinical trials, 
nine of the trials were contradicted by subsequent 
trials, underscoring the importance of confirming early 
results.70 In addition, for entirely new technologies 
such as microbicides and hiv vaccines, it is probable 
that the first candidate products to be found efficacious 
will have shortcomings, and it is likely there will need to 
be an iterative process of refinement and improvement, 
which will require substantial trials capacity. Furthermore, 
“bridging” trials are sometimes needed to determine the 
applicability of new health interventions in settings or 
populations that differ markedly from those in which  
the original trial was conducted.
t Infrastructure and training: To develop new trial sites 
in developing countries, trial sponsors, national 
governments, and donors must invest substantial 
additional resources in building physical infrastructure 
and training staff. In a multi-center trial, for example, 
the failure of a single trial site to adhere to international 
standards for good clinical practice may undermine the 
ability to draw definitive conclusions from the trial.
t Basic health services: Preparing a trial site also requires 
ensuring that there is sufficient capacity to provide 
basic health services in the community to support the 
trial, such as hiv testing and counseling, access to 
condoms and other supplies, and referrals to medical 
care when needed. These resources are vital to the 
successful conduct of any prevention trial, yet they are 
lacking in many developing countries.
t Regulatory capacity: Regulatory authorities play an 
important role in the approval and oversight of clinical 
trials. Greater regulatory capacity, particularly in 
developing countries, is needed to ensure that hiv 
prevention trial protocols are thoroughly and efficiently 
reviewed before the trials begin. (See section 3 of 
this report for a full discussion of regulatory capacity 
issues.)
Recommendations
t New investments in trials capacity: Leading sponsors 
of hiv prevention research, national governments, 
and international donors should make significant 
new investments in increasing global capacity for hiv 
prevention trials. Agencies should inventory existing 
capacity, identify specific needs in key regions, and 
prioritize sites for scaling up capacity. Increased 
resources should also be directed toward increasing 
regulatory capacity, particularly in developing 
countries, to help expedite review and approval of 
prevention trials. It is important, however, that scarce 
resources are not diverted from other health care needs, 
since many countries already face acute shortages of 
doctors and nurses.
t Collaboration on hiv prevention research: Leading 
sponsors of hiv prevention research — including 
bilateral donors, public sector biomedical research 
agencies, and leading foundations — should undertake 
joint planning and information-sharing to expedite 
developing new clinical trial sites for hiv prevention 
research. It is also critical for sponsors of prevention 
trials to collaborate with sponsors of hiv treatment 
studies, to identify opportunities for clinical trials 
capacity to be shared and used to optimal benefit across 
prevention and treatment research.
t Confirmatory trials: To ensure as little delay as possible 
in bringing new prevention tools to people in need, 
leading sponsors of hiv prevention research should 
plan — at the outset of a clinical trial — for confirmatory 
or bridging trials that may be needed after the original 
trial is completed.
Cohort Development
Clinical trials determine if a new hiv prevention method 
is effective by comparing the rate of new hiv infections 
among individuals who receive the intervention with 
the rate of new infections among a control group of 
individuals who do not receive the intervention. In order 
to yield valid results, the population being studied must 
be similar to the population that would benefit most from 
the intervention under study.71
As part of the process of mounting a major prevention 
trial, researchers undertake epidemiological studies 
to identify populations with appropriate behavioral 
and demographic characteristics to be enrolled in 
the trial — so-called “cohorts”— including those with 
high rates of hiv infection. However, in some cohorts 
currently enrolled in prevention trials, there have been 
much lower rates of infection during the trials than 
researchers had expected based on pre-trial estimates. 
For example, in one site studying pre-exposure use of 
tenofovir, hiv incidence was found to be one-third as 
high as pre-trial studies estimated it would be.72 This 
difference could stem from a variety of factors, including 
the positive impact of the other prevention services that 
are routinely provided to trial participants. Nonetheless, 
such a difference is critical, since it may require enrolling 
significantly more participants to yield statistically 
significant results.
Key issues in identifying appropriate 
cohorts for hiv prevention trials include:
t Accurately estimating hiv incidence:  
An accurate estimate of hiv 
incidence — that is, the rate of new hiv 
infections in the study population — is 
needed to enable researchers to 
project with accuracy the number of 
participants that will be needed for a 
given trial. While obtaining information 
on hiv prevalence — the proportion 
of people currently infected in a 
particular population — can be relatively 
straightforward, it is much more difficult to obtain a valid 
estimate of incidence, and to discern the characteristics of 
those who are more likely than others to become infected. 
In addition, the likely impact of other prevention services 
provided to trial participants must be taken into account 
when estimating needed trial size.
t Challenges in enrolling and retaining participants: In 
some trials, enrollment of trial participants has taken 
significantly longer than anticipated, and drop-out rates 
can be high. In some prevention trials that have enrolled 
large numbers of women of childbearing age, substantial 
numbers of participants have become pregnant and were 
required — temporarily or permanently — to drop out of 
the study. A large number of drop-outs can compromise 
the ability of a trial to arrive at valid conclusions.
Recommendations
t Enhancing models for estimating trial size: Principal 
investigators from past and ongoing prevention trials 
should collaborate with leading sponsors of prevention 
research, the World Health Organization (who), the 
U.S. Centers for Disease Control and Prevention (cdc), 
and other agencies to develop improved models for 
accurately estimating hiv incidence in trial populations 
and the number of participants that should be enrolled. 
Researchers should take into account the likelihood 
of participant drop-outs due to pregnancy and other 
factors. Until improved models are developed to 
estimate needed trial size, investigators should 
overestimate the number of participants needed, in 
order to increase the likelihood that the trial will have 
sufficient statistical power.
t New trial designs: Researchers should develop new 
trial designs that shorten the time and participants 
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FIGURE 10 . sites of current hiv prevention efficacy trials
required to identify effective interventions, as well as 
develop new methods of increasing retention of trial 
participants. In addition, to minimize the number of 
pregnant women who must discontinue or suspend 
participation in hiv prevention trials, more research is 
needed to assess the safety of new prevention methods 
during pregnancy, and to identify ways that pregnant 
women may be able to be safely retained in trials.
Prioritizing Among Multiple Candidates
At present, clinical trials capacity is typically developed 
by individual trial sponsors or investigators in order to 
test a specific product that they are researching, without 
considering how that capacity might be used by other 
sponsors or investigators. As a result, limited trials 
capacity may not be used strategically to test the most 
promising products first. In addition, trials may miss 
opportunities to undertake complementary behavioral 
studies or other research that might advance knowledge 
in the field as a whole.
In some cases, a better-financed sponsor may advance 
its own product through clinical trials even when other 
sponsors’ products appear more promising. In other 
cases, a product may be pushed forward simply because 
it is the first to be available for testing, even though 
more promising candidates are in earlier stages of 
development. This approach can waste resources, as well 
as erode general confidence in the field if disappointing 
trial results are reported. For example, in the case of 
microbicide and hiv vaccine development, while the 
mounting of large-scale trials should be viewed as 
significant progress for the field, questions have also been 
raised regarding whether the microbicide and vaccine 
candidates that have proceeded to advanced trials are 
sufficiently different from each other to warrant testing 
each among large numbers of participants.
Recommendations
t Prioritizing prevention candidates: Key stakeholders 
should develop clear criteria and mechanisms for 
prioritizing among multiple prevention methods for 
large-scale clinical trials. For example, researchers 
could agree to use comparable tests for assessing 
potential new hiv prevention methods, openly share 
information, and agree to common benchmarks at each 
stage of the research process for determining whether 
a new prevention method is sufficiently promising 
to warrant further development. Some efforts are 
already underway to increase coordination among 
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trial sponsors —including a working group of donors 
that support microbicide clinical trials, and the Global 
hiv Vaccine Enterprise — and these efforts should be 
strengthened and expanded.73
t Flexible trial sites: Where feasible, trial sites should be 
capable of being adapted for testing a range of different 
new prevention methods, including those developed 
by different sponsors and investigators, and prevention 
trial sites should be shared with hiv treatment 
research programs as appropriate. In awarding grants 
for prevention research, the major funders of such 
research should make such funding contingent on 
researchers’ agreement to create flexible research 
sites that may be used for the most appropriate and 
promising research, regardless of sponsor.
ethical conduct of 
prevention trials
All clinical trials must adhere to ethical standards that 
are recognized both internationally and in the local 
community in which the trial occurs.74 While the hiv 
prevention trials that have been conducted to date have 
adhered to these standards, new issues have arisen that 
are not addressed by existing ethical guidance, and that 
must be resolved in order to ensure the proper design 
and rapid conduct of trials. In particular, clarity is needed 
on the following issues:
t Provision of appropriate prevention counseling and 
interventions to trial participants
t Provision of antiretroviral treatment to individuals who 
become hiv-infected while participating in the trial, or 
who test positive for hiv infection while being screened 
for trial participation
t The best process for ensuring that trial participants 
give informed consent and remain properly informed 
throughout the duration of the trial
Prevention Standards for Trial Participants
Researchers are obligated to minimize potential harms 
to research participants, and trials are not permitted 
to withhold proven hiv prevention interventions from 
trial participants. Recently, this obligation has raised a 
number of issues that need to be addressed:
t Range of prevention services provided: There is not yet 
consensus on the range of existing prevention methods 
that should be provided to participants in trials of 
new hiv prevention approaches. For example, several 
governments prohibit the provision of sterile injection 
equipment, a proven strategy for the prevention of hiv 
transmission among injection drug users.75
t Quality assurance: Although the basic principles of hiv 
prevention counseling are well established, the delivery 
of such counseling can vary widely in quality. For 
example, interactive, client-centered counseling appears 
to be more effective than didactic approaches.
t Future changes in prevention standards: As new hiv 
prevention methods are successfully developed, the 
obligations of trial sponsors may evolve. For example, if 
male circumcision is confirmed as an effective strategy 
for hiv prevention, it may need to be incorporated 
in the package of prevention interventions provided 
to trial participants or their partners. Because the 
addition of new prevention tools and strategies is likely 
to decrease the rate of new hiv infections in the study 
population, the number of participants in prevention 
trials may need to increase.
Recommendations
t Guidance on prevention standards: Trial sponsors 
and international agencies should convene a standing 
committee to provide timely guidance on the list 
of prevention interventions that have been proven 
in scientific studies to be effective in reducing the 
risk of hiv transmission, and should be provided to 
participants in prevention trials. Such a committee may 
be able to be linked to existing efforts, such as groups 
established as part of unaids’s Intensifying Prevention 
effort.76
t Access to comprehensive prevention services: Trial 
sponsors should ensure access for trial participants to 
all proven prevention services, given the local context, 
including, as appropriate, evidence-based prevention 
interventions for participants who are injection drug 
users. Funding from international donors — such 
as the Global Fund to Fight aids, Tuberculosis, and 
Malaria, and the U.S. government’s President’s 
Emergency Plan for aids Relief (pepfar) — should be 
used to support access to comprehensive prevention  
for clinical trial participants.
t Monitoring: Trial sponsors should work with 
communities and others to establish mechanisms 
to monitor and document the ongoing provision of 
prevention services.
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Access to Treatment
In recent years, extensive debate has focused on the 
obligation of sponsors of hiv prevention trials to provide 
antiretrovirals and other hiv treatments to trial participants 
who contract hiv during a trial. Generally speaking, the 
initial debate over whether to provide antiretrovirals to 
trial participants who become infected has given way to 
discussions over how best to deliver the medications.77 *
A consensus is emerging that antiretroviral provision 
is an indispensable part of the agreement between trial 
sponsors and trial participants. In exchange for the 
inconvenience and potential risks of participating in 
clinical research, many believe that participants have the 
reasonable expectation of receiving antiretroviral therapy 
if they become infected with hiv during the trial. In 
addition, many in the field view antiretroviral provision 
to trial participants as an obligation that is owed to the 
communities in which trials are conducted. Dramatic 
reductions in the price of antiretrovirals in developing 
countries, combined with the demonstrated feasibility of 
administering antiretrovirals in low-income countries, 
have also influenced the debates on the obligations to 
trial participants.
Ethical guidance for hiv vaccine trials released 
in 2000 by unaids called for the provision of “care 
and treatment for hiv/aids and its complications” to 
participants who become hiv-infected during the trial, 
although the recommendations did not specify at that 
time the nature or duration of such an obligation.78 In 
2005, the International aids Society convened a meeting 
of stakeholders involved in pre-exposure tenofovir 
research to explore key issues associated with these trials, 
including access to antiretrovirals for trial participants 
who become infected.79
In recognition of the evolving discussion on this issue, 
unaids is in the process of developing updated guidance on 
antiretroviral access and other issues associated with hiv 
prevention research. In addition, a number of trial sponsors 
have made arrangements with national hiv treatment 
programs to refer trial participants who become hiv-infected 
during the trial (see the discussion of treatment for hiv 
vaccine trial participants later in this section).
Key issues currently being debated and discussed 
regarding provision of antiretroviral treatment to 
participants in hiv prevention trials include:
t Duration of obligation: It must be assumed that 
antiretroviral therapy, once initiated, is likely to be 
needed for life. Yet no consensus currently exists on 
the appropriate timeframe for ensuring treatment for 
trial participants who become hiv-infected. It should 
be noted that participants who become hiv infected 
during a trial are unlikely to need antiretroviral 
treatment until five to 10 years after they become 
infected, complicating the practical implications of 
providing treatment to these trial participants.
t Scope of obligation: There is a lack of consensus about 
whether trial sponsors are obliged to ensure access 
to antiretrovirals for individuals who are screened for 
participation in a prevention trial but are found to 
be ineligible because they are hiv-infected. Current 
standard practice is to refer would-be participants who 
are excluded due to prior hiv infection to existing 
sources of care and support, although questions have 
been raised about whether it is ethical to conduct 
prevention trials where there are severe gaps in local 
capacity to provide hiv treatment and care. At the same 
time, others, especially those from settings in which 
treatment is not available or imminent, have urged 
that researchers not avoid their communities merely 
because antiretrovirals are not widely available.
t Financial responsibility: There is no clear agreement as 
to who should be responsible for covering the long-term 
costs associated with treatment of trial participants who 
become hiv-infected, especially in countries where 
treatment services are limited or do not exist. Funding 
is also needed for scaling up treatment services in the 
trial communities generally. If trial sponsors were to 
assume the financial costs and complexity associated 
with treatment provision, this would significantly 
increase the costs of prevention research. Some have 
proposed that an independent fund be established to 
cover costs of providing antiretrovirals and other care 
and treatment to individuals who become hiv-infected 
during trial participation, or who are found to be hiv-
infected during a trial’s screening stage.80
t Community access: In addition to arranging treatment 
access for trial participants, some have argued that the 
larger communities that host prevention trials should be 
prioritized for roll-out of broad-based treatment access.
Recommendations
t Guidance on antiretroviral access: Trial sponsors and 
international agencies such as unaids and who should 
convene a broadly inclusive panel of experts — including 
clinical trial investigators, developing country health 
*  It is important to note that people who become hiv-infected 
during the course of a prevention trial do not become 
infected from the investigational tool or strategy.
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ministries, trial sponsors, private industry, ethicists, 
affected communities, and people living with hiv — to 
develop guidance on key principles for the provision of 
antiretroviral therapy to individuals who become hiv-
infected while participating in an hiv prevention trial, 
or who are found to be ineligible for the trial during the 
screening stage. This would include guidance on scope 
and duration of obligation, and financial responsibility.
t Community access: Where feasible and appropriate, 
communities that host prevention trials should be 
prioritized for introduction of antiretroviral treatment 
access. Provision of treatment to communities that host 
trials should be supported by international donors such 
as the Global Fund and pepfar.
Informed Consent
Informed consent requires (1) disclosure of critical 
information to potential trial participants, (2) 
comprehension by the potential participant of this 
information, and (3) the informed individual’s voluntary 
choice to participate in the trial.81 Although a participant’s 
informed consent is typically obtained in writing on a 
consent form, informed consent should be viewed as 
an ongoing, interactive process that permits individuals 
to obtain and understand the information they need to 
make an informed decision.
In developing countries, where literacy rates are 
low and there may be little community experience 
with clinical trials, a major challenge is to ensure that 
participants understand basic facts about the trial before 
consenting to participate. Key issues include:
t Presentation of information: It has not been fully 
determined what amount of information should be 
provided, and in what manner, to ensure that consent 
is truly informed. For example, some prevention 
studies have incorporated visual images or group 
exercises into the informed consent process as a 
strategy to communicate risks, benefits, and other 
details regarding trial participation. However, there are 
no international standards for how information should 
be presented in order to obtain informed consent.
t Verifying comprehension: Ideally, researchers should 
be able to verify the individual’s comprehension of 
critical information about the trial prior to enrollment, 
and throughout the trial. To date, most hiv prevention 
trials have included some strategy to measure 
comprehension, although optimal strategies to make 
such measurements remain unclear.
Recommendations
t Guidance on informed consent: Trial sponsors and 
international agencies should consult a broadly inclusive 
hiv vaccine trial sponsors have discussed for some time 
the ethical issues of providing antiretroviral treatment 
to participants who become infected with hiv during 
hiv vaccine clinical trials. In recent years, both the U.S. 
government-sponsored hiv Vaccine Trial Network (hvtn) 
and the International aids Vaccine Initiative (iavi) have 
established policy guidance regarding the provision of 
treatment to volunteers who become infected with hiv 
while participating in their trials. This guidance provides a 
potential model for trials of other hiv prevention methods.
iavi works with local partners to ensure the provision 
of long-term treatment and care, and in some cases, 
the partners assume responsibility for the costs of any 
needed care. If iavi’s partners are unable to do this, the 
organization commits to providing antiretroviral treatment 
for participants who become infected during a trial, for a 
period of five years after the start of treatment is clinically 
indicated.82 Similarly, hvtn has pledged to provide “long-
term” treatment to trial participants, although it has not 
specified a time-period for its treatment commitment.83
Both iavi and hvtn have developed plans for ensuring 
access to treatment. iavi has established an escrow 
account to pay for treatment needs in its trials, and hvtn 
has set up a foundation to fund treatment provision in 
its trials (hvtn is prohibited by U.S. law from providing 
treatment that is not the specific focus of research).
iavi and hvtn acknowledge that providing treatment 
over the longer term will require establishing partnerships 
with governments, nongovernmental agencies, and 
communities. In a 00 commentary in The Lancet, 
members of hvtn noted that while researchers cannot 
“reverse the global inequities” in hiv care they “can work 
with communities to develop, implement, and assess 
high-quality treatment models for participants in research 
programs, and encourage the development of sustainable 
community access to good hiv- care.”84
hiv vaccine research as a potential model 
for treatment access
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panel of experts — including clinical trial investigators, 
developing country health ministries, private industry, 
ethicists, and affected communities — to develop 
guidance on key principles for informed consent in hiv 
prevention trials.
t Assessment of comprehension: All prevention trials 
should incorporate mechanisms for assessing trial 
participants’ comprehension of information disclosed 
for purposes of obtaining informed consent. In addition 
to the participant’s informed consent upon enrollment, 
assessments of comprehension and, as needed, re-
education should occur periodically throughout the trial 
to ensure that understanding of key aspects of the trial 
does not diminish over time.
t Community participation: The Institutional Review  
Boards that oversee hiv prevention trials, as well 
as Community Advisory Boards, should include 
representatives of the communities from which trial 
participants are drawn, and people living with hiv. 
These community representatives can provide input into 
the substantive content of the information that should 
be disclosed to potential trial participants, interactive 
mechanisms for communicating key information, and 
strategies to maximize and monitor trial participants’ 
comprehension. Trial sponsors should also undertake 
efforts to assist the communities from which 
participants will be drawn in understanding the basic 
nature of clinical research — including the purpose, 
benefits, and limitations of clinical research.
t Best practices: unaids and who should work with 
trial investigators and sponsors to identify, define, and 
publish best practices with respect to informed consent 
in hiv prevention research.
engaging  
communities 
in prevention 
research
The communities in which prevention trials occur 
should be empowered to function as genuine 
partners with researchers and other stakeholders in 
conducting research that is vital to the fight against 
aids. Communities that host clinical trials must be 
educated about the research that is being conducted 
and be involved in all aspects of trial design and 
implementation. Moreover, community support is often 
vital to researchers’ ability to enroll eligible individuals 
as trial participants, to successfully complete trials, and 
to eventually support roll-out of successful tools and 
strategies.
In recent years, community concerns about plans for 
large-scale studies of tenofovir for the prevention of hiv 
transmission were a major factor in the closing of two of 
the trials.85 Although the concerns expressed about the 
tenofovir trials have varied, a common theme has focused 
on the degree to which researchers effectively engaged 
the communities in which trials would take place.86
In 2005, unaids held a series of consultations on 
creating effective partnerships between hiv prevention 
researchers and civil society, which acknowledged there 
is a need “to define new approaches to collaboration 
that will facilitate critically important research while 
at the same time being responsible and accountable to 
community needs and priorities.”87 Key issues include:
t Identification of “community”: Efforts to engage 
affected communities require researchers to define the 
community and determine who speaks on its behalf. 
In all instances, trial sponsors should forge strong 
relationships with national and district-level political 
and public health leaders. In addition, a May 2005 
expert consultation convened by the International 
aids Society concluded that “community” includes 
“potential participants, domestic and international 
activists, non-governmental organizations, and human 
rights organizations.”88
t Nature and timing of community engagement: 
Community engagement should extend beyond 
education and outreach to include the meaningful 
involvement of community representatives in 
Institutional Review Boards and/or Community 
Advisory Boards. Community involvement should 
begin well before trial recruitment begins. Community 
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representatives can have invaluable input regarding 
trial recruitment, informed consent, prevention 
counseling, and community relations.
t Optimal strategies for engaging the community: unaids 
is in the process of developing guidelines on forging 
strong partnerships between affected communities 
and hiv prevention researchers. Potential strategies 
include retaining qualified staff to conduct community 
outreach, forging formal linkages with respected ngos 
and community groups, and integrating community 
participation into Institutional Review Boards, 
Community Advisory Boards, and other institutions.
Recommendations
t Strong community partnerships: Sponsors of hiv 
prevention trials should build strong and genuine 
partnerships with the communities from which trial 
participants are drawn. Early community input should 
inform development of trial protocols, community 
education, and ongoing trial oversight.
t Building research literacy: Sponsors of hiv prevention 
trials should implement strong education programs 
to increase community awareness and understanding 
of the goals, nature, and purpose of planned research. 
This should also include reporting back to the 
community after the research has been completed.
t Guidance: International agencies such as unaids and 
who should widely disseminate formal guidance on 
best practices for engaging communities.
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Given the global health imperative of curbing the aids 
epidemic, it is vital that the world rapidly introduce 
new hiv prevention methods after they prove effective 
in trials, and avoid the historic delays in making life-
saving health interventions available to those who need 
them in poor countries. For example, for new vaccines 
for other infectious diseases, 15 years or more have 
typically passed after licensure to achieve even modest 
coverage in low- and middle-income countries.89 There 
is considerable cause for concern in the case of new hiv 
prevention methods, since the global community has not 
yet succeeded in ensuring meaningful access to current 
interventions for hiv/aids, including both prevention 
and treatment services.90
While introduction of new hiv prevention methods 
poses significant challenges, particularly in developing 
countries, there are feasible strategies to address the 
obstacles. It is too late, though, to wait until after a new 
prevention method has been shown to be effective to take 
the steps needed to expedite introduction and uptake. 
To accelerate the implementation of new prevention 
methods, development of sufficient manufacturing 
capacity will likely need to begin years in advance, 
systems to purchase and deliver the intervention 
must be put in place, public health guidance must be 
developed, and national regulatory expertise may need 
to be strengthened. In many cases, extensive operations 
research will be needed to identify the best strategies and 
tactics for addressing these implementation challenges. 
In short, the world must act now to ensure that future 
prevention breakthroughs will be accessible to those  
who need them.
3.  preparinG For access
t  Public health recommendations and regulatory capacity: 
To avoid delays in rolling out new hiv prevention 
methods after they are shown to be effective in clinical 
trials, international agencies should maintain a standing 
committee to anticipate and provide needed guidance on 
new hiv prevention methods, and regulatory agencies in 
the United States and Europe should provide assistance 
to their counterparts in developing countries in evaluating 
new prevention methods.
t  Provider training: The World Health Organization and 
others should develop provider training programs to 
promote the safe and proper use of new hiv prevention 
methods.
t  Preventing “disinhibition”: Because no new hiv 
prevention method will be 00 percent effective, strong, 
evidence-based communications and public education 
campaigns will need to accompany the introduction 
of new prevention methods, to prevent an inadvertent 
increase in risk behavior. It is essential that efforts to 
prevent behavioral “disinhibition” are monitored on an 
ongoing basis to ensure they are effective.
t  Resources for implementation: Ensuring the rapid 
deployment of new prevention methods will require 
significant new resources, both to purchase new tools 
and to support programs such as the development of 
public health guidance, provider training, and community 
education. National governments and donors should 
commit to providing the resources necessary for the 
rapid roll-out of new hiv prevention methods, as part of 
a comprehensive response to the global epidemic that 
also prioritizes current prevention approaches and hiv 
treatment and care.
preparing for access — 
key recommendations
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Even if they are accessible, new hiv prevention 
methods will only have an impact on reducing the 
number of new infections if they are used by people 
at risk, and in combination with existing prevention 
tools. Introduction of new prevention methods must 
be accompanied by communications campaigns 
to encourage adoption of new approaches, and by 
educational initiatives to ensure that these prevention 
methods are used safely and properly.
It is also vital that strong, evidence-based education 
campaigns are undertaken to avoid complacency about 
risk behavior that could result from a mistaken belief 
that new interventions are 100 percent effective. If risk 
behavior increases, modeling studies suggest this could 
undermine rather than strengthen hiv prevention efforts, 
and actually result in a growth of new hiv infections. 
Efforts to introduce new tools must be accompanied by 
strong public health steps to reinforce the importance of 
current prevention methods, and ongoing monitoring 
and evaluation to ensure that these public health steps 
are in fact effective.
This section covers the following issues that are 
critical for expediting the introduction of new hiv 
prevention methods:
t  Providing sound and timely public health 
recommendations regarding adoption of new 
prevention methods
t  Developing public and provider education strategies 
to guide the safe and proper introduction of new 
prevention methods and prevent inadvertent increases 
in risk behavior
t  Ensuring adequate resources and capacity to expedite 
introduction of new prevention methods
t  Establishing strong, sustainable systems for 
monitoring and evaluation
public health  
guidance
The availability of new hiv prevention methods could 
raise important policy questions. National decision-
makers, as well as donors and international ngos, will 
need to determine whether, and how, to integrate new 
hiv prevention methods into their health programs. In 
addition, public health guidelines must be developed to 
guide the safe and proper use of new prevention methods.
Guidance on use of new health tools is currently 
provided on an ad hoc basis. For example, in the case of 
initial efficacy results on male circumcision, informal 
discussions among key global health stakeholders resulted 
in consensus that additional studies should be completed 
before circumcision as an hiv prevention method could be 
recommended. In other instances, where consensus has 
been less clear, unaids and the World Health Organization 
(who) have convened experts to advise on the proper public 
health approach to difficult questions. In some cases, these 
consultations have led to the development of formal public 
health guidance for use by national health ministries and 
other key stakeholders.91
To be effective, guidance on emerging prevention 
methods must be timely so that donors, national policy-
makers, and program implementers can move swiftly to 
take advantage of new prevention approaches. Guidance 
must also be grounded in rigorous scientific evidence. 
Because several new prevention methods could be shown to 
be effective in the coming years, strengthening the capacity 
of national authorities, international agencies, and others to 
assess and introduce new prevention methods is an urgent 
priority. Furthermore, increasing capacity to develop and 
implement health policy on new health interventions will 
yield dividends beyond the fight against hiv/aids.
Recommendations
t  Timely guidance on emerging tools: International 
agencies should maintain a standing committee 
to anticipate and assess the need for guidance on 
the introduction and proper use of new prevention 
approaches as they are shown to be effective in clinical 
trials. Such guidance should be based on the best 
available scientific evidence, and revised as new data 
and information become available — just as guidance 
on the optimal use of hiv treatment regimens is 
regularly reviewed and updated.
t  Building national and regional policymaking capacity: 
Leading donors should support the long-term 
technical capacity of developing countries to develop 
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policies to guide the introduction and use of new 
health interventions, including new hiv prevention 
methods. As an intermediate step toward establishing 
sustainable national capacity, similarly situated 
countries in the same region or sub-region should 
collaborate in the development of public health policies 
regarding the introduction of hiv prevention methods 
that could emerge in the next several years.
t  Donor support for operations research: In many cases, 
operations research will be needed to identify the best 
strategies and tactics for rolling out new prevention 
methods. International donors — such as the Global 
Fund to Fight aids, Tuberculosis, and Malaria, and 
the U.S. government’s President’s Emergency Plan 
for aids Relief — should commit funding specifically 
to support this operations research, and to assist 
countries in applying for such funding.
regulatory 
capacity
To be eligible for use in a country, some new health 
technologies require the approval of the national 
regulatory authority. Technically sophisticated new 
hiv prevention methods — such as hiv vaccines, 
microbicides, and pre-exposure antiretroviral 
prophylaxis — will almost certainly require official 
licensure before they can be introduced in countries. 
Although who publishes a list of essential medications 
and pre-qualifies drugs and vaccines that meet accepted 
standards of quality, safety, and efficacy, the organization 
does not undertake a comprehensive regulatory review 
of new health products. Therefore, unless national 
regulators are prepared for the potentially complex issues 
that some new hiv prevention technologies are likely to 
present, significant delays could result in the introduction 
of new prevention methods. Key issues include:
t  Building national regulatory capacity: Regulatory 
systems for drugs, vaccines, and medical devices 
are weak in most developing countries, potentially 
delaying the introduction and uptake of new health 
technologies. Historically, relatively few new health 
products have been designed for initial introduction 
in developing countries, and investment in strong 
regulatory infrastructure has not been viewed as a 
major priority in developing countries. To facilitate the 
rapid introduction of new products in countries where 
they are most needed, substantially greater national 
regulatory capacity must be built.92
t  Capitalizing on regulatory capacity in high-income 
countries: Applicable laws, policies, and practices 
have historically barred regulatory authorities in 
high-income countries from undertaking regulatory 
review on behalf of another country or for products not 
intended to be used in the regulatory authority’s home 
country. In recent years, however, a growing number 
of global health experts have advocated mechanisms to 
use the regulatory capacity in high-income countries to 
buttress regulatory systems in developing countries.
t  Unanswered scientific questions: In the case of certain 
new hiv prevention technologies, such as microbicides 
and vaccines, there are unanswered scientific questions 
about what criteria should be used to make a decision 
regarding licensure — this applies to industrialized 
countries as well as developing countries.
Recommendations
t  Capacity building: Leading donors should support 
sustained efforts to increase national regulatory capacity 
in developing countries. For new prevention technologies 
such as microbicides and vaccines, for which clear 
regulatory criteria for safety and efficacy do not exist, 
donors should also provide support to international 
agencies to convene appropriate regulatory experts to 
develop guidance for regulatory review.
t  Regulatory collaboration: At the request of one or 
more developing countries, the U.S. Food and Drug 
Administration (fda), European Medicines Evaluation 
Agency (emea), and other leading regulatory bodies 
should be prepared to undertake a regulatory review 
and analysis of a complete regulatory submission 
regarding new health interventions intended for 
primary use in developing countries, including new 
hiv prevention methods. Upon completion of the 
review or analysis, the regulatory body would provide 
the requesting party with a summary of findings, with 
ultimate licensure decisions remaining the province of 
national regulatory authorities in countries where the 
new tool or strategy will be used. fda, emea, and other 
leading regulatory bodies should set aside sufficient 
budget to support such regulatory reviews.
It should be noted that under a new initiative by 
emea, European regulators will, at the request of a 
developing country, review and analyze regulatory 
submissions for new health products that are designed 
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for primary or exclusive use in developing countries. 
Under this new policy, licensure of any new product 
ultimately remains the province of individual national 
regulatory authorities.93
t  Regional collaboration: Regional collaboration 
among national regulators could strengthen the 
ability of developing countries to expedite the review 
and approval of promising new hiv prevention 
methods. By pooling regulatory expertise, regions 
could capitalize on available capacity to accelerate the 
introduction of new products. Supported by donors, 
regulatory bodies in different regions should develop 
strategic plans for timely, collaborative review and 
information-sharing regarding new hiv prevention 
methods that are candidates for licensure.
t  Harmonization: International efforts to harmonize 
regulatory requirements for new health interventions 
should be broadened to include national regulatory 
authorities from developing countries. Although 
national regulatory agencies in North America, 
Europe, and Japan have worked under the umbrella 
of the International Conference on Harmonization 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use to reduce the 
duplication and expense associated with regulatory 
approval in multiple countries, this process has yet to 
address regulatory processes in developing countries.94
public and 
provider  
education
Effective communication and education strategies are 
vital to the introduction of new hiv prevention tools and 
strategies. Individuals will not adopt a new prevention 
method if they are not aware of it, and sustained marketing 
efforts may be needed to promote uptake of some new 
methods. In addition, training may be required — for 
providers as well as consumers — to ensure that new 
prevention methods are used properly. Most importantly, 
strong, proactive communication and education strategies 
will be essential to ensure that the introduction of new 
prevention methods does not inadvertently lead to overall 
increases in sexual risk behavior.
Community Education and Marketing
Proof in clinical trials that a new prevention method, 
such as male circumcision, is safe and effective will 
not automatically result in its widespread adoption by 
consumers or providers. And if individuals who adopt 
a new prevention method use it improperly, this could 
diminish its effectiveness in reducing the risk of hiv 
transmission.
For example, studies indicate that education and 
experience using condoms significantly reduce the 
likelihood of condom failure.95 As new hiv prevention 
methods emerge, community education initiatives will 
be needed to raise awareness of the new method and to 
encourage its adoption and proper use. Social marketing 
approaches to community education have proven to be 
highly effective in increasing consumer adoption of new 
health products.96
Acceptability studies can inform efforts to ensure 
broad and correct adoption of new prevention methods. 
Developers of candidate microbicides, for example, have 
performed extensive research on the acceptability of the 
products among sexually active women and their male 
partners.97 In the case of male circumcision, surveys 
and anecdotal data indicate widespread demand for 
circumcision in some parts of Africa,98 although there 
is a need for further research, given strong cultural 
norms and practices surrounding circumcision in many 
countries. And in Zimbabwe, researchers conducted 
a female diaphragm acceptability study,99 and are 
continuing to assess acceptability by the community and 
providers while they test the diaphragm’s effectiveness 
for hiv prevention.

Recommendations
t  Acceptability studies: Sponsors of efficacy trials of new 
hiv prevention methods should undertake studies to 
assess the acceptability of the method to consumers 
and, when appropriate, to their sexual partners. 
These studies should also assess acceptability among 
providers.
t  Financing: Additional donor financing for new 
prevention methods should include funding for 
community education initiatives and social marketing 
campaigns to identify and implement strategies to 
encourage adoption and proper use of new prevention 
methods.
Preventing Behavioral “Disinhibition”
It is critical that the introduction of new hiv prevention 
methods does not inadvertently lead people to become 
complacent about risk behavior.100 If the introduction of 
a new prevention method is accompanied by an overall 
increase in risk behaviors, the protective benefits of the 
new method, as well as of other prevention measures, 
may be canceled out. In the most extreme case, a 
“disinhibiting” effect of a new prevention method could 
result in an actual increase in the number of new hiv 
infections. The need to address potential disinhibition 
as a result of prevention advances is especially important 
for the classes of prevention methods currently under 
development, as all would offer only partial protection 
against infection. Key issues include:
t  Community education: Integration of new prevention 
methods into national aids programs should be 
accompanied by strong, sustained campaigns to 
educate affected communities regarding the benefits 
and limitations of the new methods. These campaigns 
must be grounded in rigorous scientific evidence of 
effectiveness. Both donors and national authorities 
should understand that the costs of introducing new 
prevention methods include substantial investments in 
education to avoid disinhibition.
t  Monitoring of behavioral changes: To inform public 
health measures to prevent disinhibition, behavioral 
surveillance will be needed to assess the effect, if any, of 
new hiv prevention approaches on risk behavior decision-
making. Currently, behavioral surveillance systems are 
extremely weak in many developing countries.
Recommendations
t  Education campaigns: It is essential that the 
introduction of new prevention methods be 
accompanied by strong, sustained, well-financed public 
education campaigns that warn against disinhibition, 
emphasize the benefits and limitations of new 
prevention methods, and encourage use of the full 
range of proven prevention measures, including sexual 
abstinence, partner reduction, and condoms. The 
development of these campaigns should be informed 
by social science research to identify the most effective 
education strategies.
behavioral disinhibition—
lessons from treatment 
access
As new hiv prevention methods are introduced, it is 
critical to ensure that risk behavior does not increase 
as a result of complacency about hiv. Researchers 
have modeled the impact of even small increases 
in risk behavior as the result of expanded treatment 
access, which could also have a “disinhibiting” effect 
on risk behavior.
For example, in India, projections by the World 
Bank estimate that even small decreases in condom 
use as a result of expanded access to treatment 
could actually result in a loss of millions of life-
years. However, if treatment access is accompanied 
by strong prevention campaigns, and condom use 
remains stable or increases, expanded access to 
treatment and prevention together could save millions 
of life-years.
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t  Technical support: who, the Centers for Disease 
Control and Prevention, and other leading public 
health agencies should enhance their technical support 
to countries to improve behavioral surveillance systems 
for detecting potential disinhibiting effects of new 
prevention methods. Donors should prioritize financial 
assistance to countries to strengthen public health 
surveillance and the development of effective public 
education campaigns regarding new hiv prevention 
methods.
Provider Training
As new hiv prevention methods are successfully 
developed, health care providers and community workers 
will require training in the proper use of new prevention 
approaches. In many developing countries, for example, 
few health care providers have experience in circumcising 
adult males, and when circumcision is improperly 
performed, the procedure can result in serious medical 
complications or death. The problem of health worker 
training is compounded by the fact that many developing 
countries suffer acute shortages of qualified health care 
personnel in general.
Recommendation
t  Training: With targeted financial support from donors, 
who should develop regional and country-level 
training measures to promote proper use of new hiv 
prevention methods. In some cases it may be advisable 
to implement accreditation and supervision programs, 
although such efforts would need to account for the 
fact that in many countries, traditional healers and 
religious leaders play a critical role in providing and 
advising on health care.
supply and  
delivery
Substantial financial investments will be needed to build 
the long-term capacity essential for ensuring the adequate 
supply and swift delivery of new hiv prevention methods 
in developing countries.
Procurement and Supply Management
Some new hiv prevention methods will present 
significant procurement and supply management 
challenges for the developing countries most seriously 
affected by hiv. In the case of technically sophisticated 
prevention methods — such as hiv vaccines, 
microbicides, and antiretrovirals for prophylaxis —  
the cost of the new prevention methods will likely 
substantially exceed most countries’ ability to purchase 
them. In countries where annual per capita health 
spending is especially constrained, even inexpensive 
prevention options will compete with other national 
priorities for budget allocations. In addition, recent 
experience in the introduction of antiretrovirals for the 
treatment of hiv underscores the potential for logistical 
issues to impede introduction of life-saving health 
interventions, as countries have found that roll-out of  
hiv treatment requires the capacity to forecast demand 
and manage supplies on a large scale.101
In addition to the need for increased and sustained 
political commitment to provide resources to purchase 
and deliver new prevention methods, key issues include:
t  Estimating demand: Ensuring sufficient supply 
and, if necessary, manufacturing capacity for new 
hiv prevention methods requires accurate demand 
forecasting. Future demand for new hiv prevention 
methods will depend on a variety of variables, 
including existence of a means to purchase the 
product, accessible delivery systems, and consumer 
acceptance, among other factors. Demand is not static 
and can be influenced by external factors, such as 
donor assistance and social marketing.
t  Country-level systems for procurement and supply 
management: Limited or non-existent national capacity 
to manage the purchase, delivery, and inventory of 
health commodities has limited countries’ ability 
to rapidly expand access to antiretroviral therapy in 
recent years. Similar impediments could slow uptake 
for new prevention methods, although experience 
gained through the global push for universal hiv/aids 
treatment access is rapidly helping countries build 
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capacity and expertise that will assist in expediting 
introduction of new prevention methods.
Recommendations
t  Political commitment to provide resources: Both 
developed country donors and developing country 
leaders should honor the commitments made at the 
United Nations General Assembly Special Session 
on hiv/aids102 to support the rapid introduction of 
new methods for the prevention of hiv transmission. 
In addition, further action is needed on measures 
currently being examined to increase resources for 
international health and development, including 
advance purchase mechanisms for new prevention 
methods,103 use of securities markets to generate 
funds for health and development initiatives (e.g., the 
International Finance Facility for Immunization),104  
and implementation of a tax on air travel.105
t  Pricing agreements: With the close cooperation of 
developing countries and multilateral institutions, leading 
donors should implement, monitor, and refine new 
mechanisms to purchase new prevention commodities  
at favorable prices for developing countries.
t  Capacity building: Countries should receive targeted 
support to build the capacity to develop timely analyses  
of future demand for emerging hiv prevention 
methods such as microbicides and to implement 
sound purchase, delivery, and supply management 
systems for new prevention methods.
Manufacturing Capacity
For technologies such as hiv vaccines and microbicides, 
several years can be required to build sufficient 
production capacity, and manufacturers may need to 
make decisions regarding initial manufacturing capacity 
in advance of initial regulatory licensure — that is, before 
large-scale efficacy trials have been completed.106 Even 
for less complicated technologies, it is often challenging 
to gauge future demand and to calibrate manufacturing 
capacity to meet anticipated demand. Key issues include:
t  Creating and sustaining sufficient manufacturing 
capacity: Even for relatively simple technologies, 
construction of manufacturing capacity to meet global 
demand involves substantial financial outlays and 
adherence to regulatory requirements. In many cases, 
owners of new prevention technologies are small 
biotech companies, academic centers, or not-for-profit 
organizations that have limited access to capital.
Recommendation
t  Innovative mechanisms for ensuring sufficient 
manufacturing capacity: Leading donors, multilateral 
organizations, and developing countries should 
collaborate in the development of strategies to ensure 
timely and sufficient manufacturing capacity to meet 
global demand for a wide variety of new hiv prevention 
methods.
monitoring and 
evaluation
A key role of regulatory agencies in developed countries 
is to monitor health interventions after they are approved 
for use. Such monitoring helps to document the 
impact of new tools and strategies, detect side effects 
not identified in clinical trials, and refine public health 
guidelines for optimal use of health interventions. In 
the case of side effects, for example, use of improper 
circumcision techniques by untrained practitioners can 
result in severe infections, permanent disability, and  
even death, underscoring the need for strong quality 
assurance mechanisms.
At the same time, documentation of the public 
health impact of new interventions will help generate 
momentum for investment in even better tools and 
strategies for the future.
Recommendation
t  Quality assurance: Additional donor financing for new 
hiv prevention methods should include sufficient 
support for the implementation and maintenance of 
strong national monitoring, evaluation, and quality 
assurance programs. These programs should include 
components that monitor for potential disinhibiting 
effects of new hiv prevention methods.

references
1. UNAIDS, Report on the Global AIDS Epidemic, 
2006.
2. UNAIDS, AIDS Epidemic Update, 2005.
3. UNAIDS, Women and HIV/AIDS: Confronting 
the Crisis, 2004.
4. UNAIDS, Resource Needs for an Expanded 
Response to AIDS in Low- and Middle-Income 
Countries, 2005.
5. USAID et al., Coverage of Selected Services for 
HIV/AIDS Prevention, Care, and Support in Low- 
and Middle-Income Countries in 2003, 2004. See 
also Global HIV Prevention Working Group, 
Access to HIV Prevention: Closing the Gap, 2003.
6. J. Stover et al., The global impact of scaling 
up HIV/AIDS prevention programs in low- and 
middle-income countries, Science; published 
online February 2, 2006.
7. For a review of the effectiveness of current 
HIV prevention methods, see Global HIV 
Prevention Working Group, Global Mobilization 
for HIV Prevention: A Blueprint for Action, 2002 
(and studies cited therein). See also J. Auerbach 
et al., Overview of effective and promising 
interventions to prevent HIV infection, in D. 
Ross et al. (eds.), Preventing HIV/AIDS in Young 
People: A Systematic Review of the Evidence From 
Developing Countries, 2006.
8. Ibid., UNAIDS, Epidemic Update, 2005.
9. Ibid., UNAIDS, Women and AIDS, 2004.
10. Ibid., Global HIV Prevention Working 
Group, Blueprint for Action, 2002 (and studies 
cited therein).
11. H. Weiss et al., Male circumcision and 
risk of HIV infection in sub-Saharan Africa: 
a systematic review and meta-analysis, AIDS 
2000;14:2361-70.
12. S. Reynolds et al., Male circumcision and 
risk of HIV-1 and other sexually transmitted 
infections in India, Lancet 2004;363:1039-40.
13. B. Auvert et al., Randomized, controlled 
intervention trial of male circumcision for 
reduction of HIV infection risk: the ANRS 1265 
trial, PLoS Med 2005;2:e298.
14. UNAIDS, Statement on South African Trial 
Findings Regarding Male Circumcision and HIV, 
July 26, 2005.
15. R. Gray et al., Male circumcision and the 
risks of female HIV and STI acquisition in Rakai, 
Uganda, abstract presented at 13th Conference 
on Retroviruses and Opportunistic Infections, 
2006.
16. B. Williams et al., The potential impact 
of male circumcision on HIV in sub-Saharan 
Africa, PLoS Med 2006;3:e262.
17. J. Krieger et al., Adult male circumcision: 
results of a standardized procedure in Kisumu 
District, Kenya, BJU Int 2005;96:1109-13.
18. T. Moench et al., Preventing disease by 
protecting the cervix: the unexplored promise 
of internal vaginal barrier devices, AIDS 
2001;15:1595-1602.
19. A. van der Straten et al., Predictors of 
diaphragm use as a potential sexually transmitted 
disease/HIV prevention method in Zimbabwe, 
STD 2005;32:64-71.
20. J. Buck et al., Barrier method preference and 
perceptions among Zimbabwean women and 
their partners, AIDS Behav 2005;9:415-22.
21. L. Guay et al., Intrapartum and neonatal 
single-dose nevirapine compared with zidovudine 
for prevention of mother-to-child transmission 
of HIV-1 in Kampala, Uganda: HIVNET 012 
randomized trial, Lancet 1999;354:795-802. See 
also Institute of Medicine, Review of the HIVNET 
012 Perinatal HIV Prevention Study, 2005.
22. D. Cardo et al., A case-control study of 
HIV seroconversion in health care workers 
after percutaneous exposure, New Eng J Med 
1997;337:1485-90.
23. For an overview of tenofovir’s drug profile, 
see J. Gallant & S. Deresinski, Tenofovir 
disoproxil fumarate, Clin Infect Dis 2003;37:944-
50.
24. C. Tsai et al., Prevention of SIV infection in 
macaques by (R)-9-(2-phosphonylmethoxypropy
l)adenine, Science 1995;270:1197-9.
25. S. Subbarao et al., Chemoprophylaxis 
with oral tenofovir disoproxil fumarate (TDF) 
delays but does not prevent infection in rhesus 
macaques given repeated rectal challenges of 
SHIV, abstract presented at 12th Conference 
on Retroviruses and Opportunistic Infections, 
2005.
26. For an overview of emtricitabine’s drug 
profile, see S. Michael et al., Efficacy and safety 
of emtricitabine vs. stavudine in combination 
therapy in antiretroviral-naive patients: a 
randomized trial, JAMA 2004;292:180-190.
27. W. Heneine et al., Prevention of rectal 
SHIV transmission in macaques by tenofovir/
FTC combination, abstract presented at 13th 
Conference on Retroviruses and Opportunistic 
Infections, 2006.
28. G. Szekeres et al., Anticipating the Efficacy of 
HIV Pre-Exposure Prophylaxis (PREP) and the 
Needs of At-Risk Californians, 2004.
29. Ibid.
30. E. Freeman et al., Herpes simplex virus 2 
infection increases HIV acquisition in men and 
women: systematic review and meta-analysis of 
longitudinal studies, AIDS 2006;20:78-83.
31. N. Nagot et al., Effect of HSV-2 suppressive 
therapy on HIV-1 genital shedding and plasma 
viral load: a proof-of-concept randomized double-
blind placebo controlled trial (ANRS 1285 
trial), abstract presented at 13th Conference 
on Retroviruses and Opportunistic Infections, 
2006.
32. M. Reyes et al., Acyclovir-resistant 
genital herpes among persons attending 
sexually transmitted disease and human 
immunodeficiency virus clinics, Arch Intern Med 
2003;163:76-80.
33. J. Trussell et al., Comparative contraceptive 
efficacy of the female condom and other barrier 
methods, Fam Plan Perspect 1994;26:66-72.
34. M. Gross et al., Use of Reality female 
condoms for anal sex by U.S. men who have sex 
with men, Am J Pub Health 1999;89:1739-41.
35. WHO, Substitution Maintenance Therapy in 
the Management of Opioid Dependence and HIV 
Prevention, 2004.
36. Ibid., UNAIDS, Global Report, 2006.
37. Ibid.
38. Voluntary HIV-1 Counseling and Testing 
Efficacy Study Group, Efficacy of voluntary 
HIV-1 counseling and testing in individuals 
and couples in Kenya, Tanzania, and Trinidad: a 
randomized trial, Lancet 2000;356:103-12.
39. N. Crepaz & G. Marks, Toward an 
understanding of sexual risk behavior in people 
living with HIV: a review of social, psychological, 
and medical findings, AIDS 2002;16:135-49.
40. CDC, Incorporating HIV prevention into the 
medical care of persons living with HIV, MMWR 
2003;52:1-24.
41. T. Quinn et al., Viral load and heterosexual 
transmission of human immunodeficiency virus 
type 1, N Eng J Med 2000;342:921-9.
42. A. Hauri et al., The global burden of disease 
attributable to contaminated injections given in 
health care settings, Int J STD AIDS 2004;15:7-
16.
43. WHO, Statement on the Use of Auto-Disable 
Syringes in Immunization Services, 1999.
44. WHO, The Safety of Immunization Practices 
Improves Over Last Five Years, but Challenges 
Remain, news release, November 11, 2005.
45. W. Hogrefe et al., Detection of herpes 
simplex virus type 2-specific immunoglobulin G 
antibodies in African sera by using recombinant 
gG2, Western Blotting, and gG2 inhibition, J 
Clin Microbiol 2002;40:3635-40.
46. E. Freeman et al., The impact of HSV-2 on 
new HIV infections increases over time: the 
changing role of sexually transmitted infections 
in sub-Saharan African HIV epidemics, abstract 
presented at 16th Biennial Meeting of the 
International Society for Sexually Transmitted 
Diseases Research, 2005.
47. For an overview of potential microbicide 
approaches, see J. Weber et al., The development 
of vaginal microbicides for the prevention of HIV 
transmission, PLoS Med 2005;2:e142. See also J. 
Moore, Topical microbicides become topical, 
New Eng J Med 2005;352:298-300.
48. For up-to-date information on microbicide 
candidates in development, see the websites of the 
Global Campaign for Microbicides (www.global-
campaign.org), and the Alliance for Microbicide 
Development (www.microbicide.org).
49. For example, R. Veazey et al., Protection 
of macaques from vaginal SHIV challenge by 
vaginally delivered inhibitors of virus-cell fusion, 
Nature 2005;438:99-102.
50. For example, K. Barnhart et al., BufferGel with 
diaphragm found to be an effective contraceptive 
in two phase II/III trials, abstract presented at 
Microbicides 2006 conference, 2006.
51. For an overview of rectal microbicide 
research, see International Rectal Microbicide 
Working Group, Rectal Microbicides: Investment 
and Advocacy, 2006 (and studies cited therein).
52. Public Health Working Group, Microbicides 
Initiative, The Public Health Benefits of 
Microbicides in Lower-Income Countries: Model 
Projections, 2002.
53. International Family Health et al., The 
Potential Impact of Microbicides in Bagalkot 
District, Karnataka, India: Model Projections and 
Implications for Product Promotion, 2004.
54. International Family Health et al., A 
Comparison of the Potential Impact of Microbicides 
in Two Contrasting African Settings, Johannesburg, 
South Africa, and Cotonou, Benin, 2004.
55. See J. Mantel et al., Microbicide acceptability 
research: current approaches and future 
directions, Soc Sci Med 2005;60:319-30.
56. For a comprehensive review of the state 
of HIV vaccine research, see Coordinating 
Committee of the Global HIV Vaccine Enterprise, 
The Global HIV Vaccine Enterprise Scientific 
Strategic Plan, PLoS Med 2005;2:e25. See also 
International AIDS Vaccine Initiative, AIDS 
Vaccine Blueprint 2006: Actions to Strengthen 
Global Research and Development, 2006. In 
addition, see AIDS Vaccine Advocacy Coalition, 
AIDS Vaccines: The Next Frontiers, 2006.
57. For example, J. Shiver et al., Replication-
incompetent adenoviral vaccine vector elicits 
effective anti-immunodeficiency-virus immunity, 
Nature 2002;415:331-5.
58. D. Follmann, An independent analysis of 
the effect of race in VAX004, abstract presented 
at 11th Conference on Retroviruses and 
Opportunistic Infections, 2004.
59. Databases of HIV vaccine candidates in 
clinical trials are maintained by the International 
AIDS Vaccine Initiative (www.iavi.org) and the 
HIV Vaccine Trials Network’s Pipeline Project 
(chi.ucsf.edu/vaccine).
60. G. Pantaleo & R. Koup, Correlates of immune 
protection in HIV-1 infection: what we know, 
what we don’t know, what we should know, Nat 
Med 2004;10:806-10.
61. Ibid., Global HIV Vaccine Enterprise, 
Scientific Strategic Plan, 2005. See also R. 
Klausner et al., The need for a global HIV vaccine 
enterprise, Science 2003;300:2036-9.
62. World Bank, The Epidemiological Impact of an 
HIV/AIDS Vaccine in Developing Countries, 2002.
63. Global Forum for Health Research, 
Monitoring Financial Flows for Health Research, 
2004.
64. HIV Vaccines and Microbicides Resource 
Tracking Group, Tracking Funding for Microbicide 
Research and Development: Estimates of Annual 
Investments, 2005. HIV Vaccines and Microbicides 
Resource Tracking Group, Tracking Funding for 
Preventive HIV Vaccine Research and Development: 
Estimates of Annual Investments and Expenditures, 
2005. See also www.hivresourcetracking.org.
65. Ibid.
66. A. Batson, The problems and promise of 
vaccine markets in developing countries, 
Health Affairs 2005;24:690-3. See also M. Pauly, 
Improving vaccine supply and development: who 
needs what? Health Affairs 2005;24:680-9.
67. Center for Global Development, Making 
Markets for Vaccines: Ideas to Action, 2005.
68. For an overview of issues concerning clinical 
trial design and conduct, see S. Chow & J. Liu, 
Design and Analysis of Clinical Trials: Concepts 
and Methodologies, 2nd Edition, 2003.
69. In the case of community-based sexually 
transmitted disease control as an HIV prevention 
strategy, initial trial results indicating a high level 
of effectiveness were followed by results from 
other studies that failed to detect a significant 
benefit. For a discussion, see P. Hitchcock & L. 
Fransen, Preventing HIV infection: lessons from 
Mwanza and Rakai, Lancet 1999;353:513-5.
70. J. Ioannidis, Contradicted and initially 
stronger effects in highly cited clinical research, 
JAMA 2005;294:218-28.
71. S. Buchbinder, HIV vaccine efficacy trials: 
lessons learned and future directions, abstract 
presented at 11th Conference on Retroviruses 
and Opportunistic Infections, 2004.
72. Family Health International & Cellegy 
Pharmaceuticals, Joint Statement on Savvy Phase 
III Trial in Ghana to Test the Effectiveness of Savvy 
Gel in Preventing HIV, November 8, 2005.
73. Ibid., Global HIV Vaccine Enterprise, 
Scientific Strategic Plan, 2005.
74. For an overview of ethical standards for 
clinical trials, see R. Levine, Ethics and Regulation 
of Clinical Research, 2nd Edition, 1988.
75. For a review of the evidence on the 
effectiveness of prevention strategies for injection 
drug users, see S. Hurley et al., Effectiveness 
of needle exchange programs for prevention 
of HIV infection, Lancet 1997;349:1797-800. 
See also A. Wodak & A. Cooney, Do needle 
syringe programs reduce HIV infection among 
injecting drug users? A comprehensive review 
of the international evidence, Sub Use & Misuse 
2006;41:777-813.
76. UNAIDS, Intensifying HIV Prevention, 2005.
77. WHO, Treating people with intercurrent 
infection in HIV prevention trials: report from a 
WHO/UNAIDS consultation, AIDS 2004;18:W1-
12. See also A. Forbes, Moving toward assured 
access to treatment in microbicide trials, PLoS 
Med 2006;3:e153.
78. UNAIDS, Ethical Considerations in HIV 
Preventive Vaccine Research, 2000.
79. International AIDS Society, Building 
Collaboration to Advance HIV Prevention: Global 
Consultation on Tenofovir Pre-Exposure Prophylaxis 
Research, 2005.
80. J. Ananworanich et al., Creation of a drug 
fund for post-clinical trial access to antiretrovirals, 
Lancet 2004;364:101-2.
81. For an overview of issues related to informed 
consent, see C. McGrory et al., Informed Consent 
in HIV Prevention Trials: Report of an International 
Workshop, 2006.
82. S. Berkley, Thorny issues in the ethics of 
AIDS vaccine trials, Lancet 2003;362:992.


83. D. Fitzgerald et al., Provision of treatment 
in HIV-1 vaccine trials in developing countries, 
Lancet 2003;362:993-4.
84. Ibid.
85. K. Page-Shafer et al., HIV prevention 
research in a resource-limited setting: the 
experience of planning a trial in Cambodia, 
Lancet 2005;366:1499-503.
86. E. Mills et al., Designing research in 
vulnerable populations: lessons from HIV 
prevention trials that stopped early, BMJ 
2005;331:1403-6.
87. UNAIDS, Creating effective partnerships 
for HIV prevention trials: report of a UNAIDS 
consultation, AIDS 2006;20:W1-11.
88. Ibid., International AIDS Society, Consultation 
on Tenofovir, 2005.
89. J. Clemens & L. Jodar, Introducing new vaccines 
into developing countries: obstacles, opportunities 
and complexities, Nat Med 2005;11:S12-5. See also 
J. Andrus & J. Fitzsimmons, Introduction of new 
and underutilized vaccines: sustaining access, 
disease control, and infrastructure development, 
PLoS Med 2005;2:e286.
90. Ibid., USAID et al., Coverage of Selected 
Services for HIV, 2004. See also WHO, Progress 
on Global Access to HIV Antiretroviral Therapy: 
An Update on “3 by 5,” 2006.
91. For example, UNFPA et al., New Data on 
the Prevention of Mother-to-Child Transmission 
of HIV and Their Policy Implications: Technical 
Consultation, 2001.
92. For a discussion of issues involved in 
strengthening the national regulatory capacity of 
developing countries, see WHO, Aide-Memoire: 
Strengthening National Regulatory Authorities, 2003.
93. Article 58 of European Commission 
regulation 726/2004 allows the EMEA’s 
Committee for Medicinal Products for Human 
Use to provide opinions on products intended 
for markets outside of the European Union.
94. For information on ICH, see www.ich.org.
95. U.S. National Institute of Allergy and 
Infectious Diseases, Scientific Evidence on 
Condom Effectiveness for Sexually Transmitted 
Disease Prevention, 2001.
96. For example, UNAIDS, Condom Social 
Marketing: Selected Case Studies, 2000.
97. Ibid., J. Mantel et al., Microbicide acceptability 
research, 2005.
98. Ibid., J. Krieger et al., Adult male 
circumcision, 2005.
99. Ibid., J. Buck et al., Barrier method 
preference, 2005.
100. For a discussion of disinhibition in the 
context of the potential future introduction of 
tenofovir pre-exposure prophylaxis, see AIDS 
Vaccine Advocacy Coalition, Will a Pill a Day 
Prevent HIV?: Anticipating the Results of the 
Tenofovir PREP Trials, 2005. For a discussion of 
disinhibition in the context of expanded access 
to HIV treatment, see M. Over et al., HIV/AIDS 
Treatment and Prevention in India: Modeling the 
Costs and Consequences, 2004.
101. Ibid., WHO, Progress on Global Access to 
Antiretroviral Therapy, 2006.
102. United Nations, Declaration of Commitment 
on HIV/AIDS, United Nations General Assembly 
Special Session on HIV/AIDS, 2001 (see 
paragraph 70).
103. Ibid., Center for Global Development, 
Making Markets for Vaccines, 2005.
104. See www.iffim.com.
105. Reuters, 13 Countries Join Forces on Air 
Ticket Tax for Poor, March 1, 2006.
106. International AIDS Vaccine Initiative, 
Speeding the Manufacture of an HIV Vaccine: 
Policy Issues and Options, 2005.

this report is available at www.gatesfoundation.org, www.kff.org, and www.care.org
